<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
<journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLoS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30735520</article-id>
<article-id pub-id-type="pmc">6368302</article-id>
<article-id pub-id-type="doi">10.1371/journal.pone.0211901</article-id>
<article-id pub-id-type="publisher-id">PONE-D-18-22994</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Genetics</subject>
<subj-group>
<subject>Mutation</subject>
<subj-group>
<subject>Missense Mutation</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Research and Analysis Methods</subject>
<subj-group>
<subject>Database and Informatics Methods</subject>
<subj-group>
<subject>Bioinformatics</subject>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Genetics</subject>
<subj-group>
<subject>Mutation</subject>
<subj-group>
<subject>Point Mutation</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Medicine and Health Sciences</subject>
<subj-group>
<subject>Neurology</subject>
<subj-group>
<subject>Epilepsy</subject>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Medicine and Health Sciences</subject>
<subj-group>
<subject>Neurology</subject>
<subj-group>
<subject>Epilepsy</subject>
<subj-group>
<subject>Status Epilepticus</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Genetics</subject>
<subj-group>
<subject>Mutation</subject>
<subj-group>
<subject>Nonsense Mutation</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Psychology</subject>
<subj-group>
<subject>Behavior</subject>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Social Sciences</subject>
<subj-group>
<subject>Psychology</subject>
<subj-group>
<subject>Behavior</subject>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Research and Analysis Methods</subject>
<subj-group>
<subject>Bioassays and Physiological Analysis</subject>
<subj-group>
<subject>Electrophysiological Techniques</subject>
<subj-group>
<subject>Membrane Electrophysiology</subject>
<subj-group>
<subject>Patch Clamp Techniques</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title><italic>In vivo</italic>, <italic>in vitro</italic> and <italic>in silico</italic> correlations of four <italic>de novo SCN1A</italic> missense mutations</article-title>
<alt-title alt-title-type="running-head">Correlations of <italic>SCN1A</italic> missense mutations</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Nissenkorn</surname>
<given-names>Andreea</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Almog</surname>
<given-names>Yael</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Adler</surname>
<given-names>Inbar</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Safrin</surname>
<given-names>Mary</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brusel</surname>
<given-names>Marina</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marom</surname>
<given-names>Milit</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bercovich</surname>
<given-names>Shayel</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<xref ref-type="aff" rid="aff006">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yakubovich</surname>
<given-names>Daniel</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff007">
<sup>7</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tzadok</surname>
<given-names>Michal</given-names>
</name>
<role content-type="http://credit.casrai.org/">Resources</role>
<xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ben-Zeev</surname>
<given-names>Bruria</given-names>
</name>
<role content-type="http://credit.casrai.org/">Resources</role>
<xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-2617-2276</contrib-id>
<name>
<surname>Rubinstein</surname>
<given-names>Moran</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref>
<xref ref-type="aff" rid="aff008">
<sup>8</sup>
</xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label>
<addr-line>Service for Rare Disorders, The Edmond and Lily Safra Children’s Hospital, Chaim Sheba Medical Center, Tel HaShomer, Israel</addr-line></aff>
<aff id="aff002"><label>2</label>
<addr-line>Pediatric Neurology Unit, The Edmond and Lily Safra Children’s Hospital, Chaim Sheba Medical Center, Tel HaShomer, Israel</addr-line></aff>
<aff id="aff003"><label>3</label>
<addr-line>Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel</addr-line></aff>
<aff id="aff004"><label>4</label>
<addr-line>Goldschleger Eye Research Institute, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel</addr-line></aff>
<aff id="aff005"><label>5</label>
<addr-line>Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel</addr-line></aff>
<aff id="aff006"><label>6</label>
<addr-line>The Arrow Project, The Edmond and Lily Safra Children’s Hospital, Chaim Sheba Medical Center, Tel HaShomer, Israel</addr-line></aff>
<aff id="aff007"><label>7</label>
<addr-line>Neonatal Intensive Care, Edmond and Lily Safra Children’s Hospital, Chaim Sheba Medical Center, Tel HaShomer, Israel</addr-line></aff>
<aff id="aff008"><label>8</label>
<addr-line>The Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor">
<name>
<surname>Biagini</surname>
<given-names>Giuseppe</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"></xref>
</contrib>
</contrib-group>
<aff id="edit1">
<addr-line>University of Modena and Reggio Emilia, ITALY</addr-line>
</aff>
<author-notes>
<fn fn-type="COI-statement" id="coi001">
<p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email>moranrub@tauex.tau.ac.il</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>8</day>
<month>2</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>14</volume>
<issue>2</issue>
<elocation-id>e0211901</elocation-id>
<history>
<date date-type="received">
<day>3</day>
<month>8</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>1</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 Nissenkorn et al</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>Nissenkorn et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="pone.0211901.pdf"></self-uri>
<abstract>
<p>Mutations in the <italic>SCN1A</italic> gene, which encodes for the voltage-gated sodium channel Na<sub>V</sub>1.1, cause Dravet syndrome, a severe developmental and epileptic encephalopathy. Genetic testing of this gene is recommended early in life. However, predicting the outcome of <italic>de novo</italic> missense <italic>SCN1A</italic> mutations is difficult, since milder epileptic syndromes may also be associated. In this study, we correlated clinical severity with functional <italic>in vitro</italic> electrophysiological testing of channel activity and bioinformatics prediction of damaging mutational effects. Three patients, bearing the mutations p.Gly177Ala, p.Ser259Arg and p.Glu1923Arg, showed frequent intractable seizures that had started early in life, with cognitive and behavioral deterioration, consistent with classical Dravet phenotypes. These mutations failed to produce measurable sodium currents in a mammalian expression system, indicating complete loss of channel function. A fourth patient, who harbored the mutation p.Met1267Ile, though presenting with seizures early in life, showed lower seizure burden and higher cognitive function, matching borderland Dravet phenotypes. In correlation with this, functional analysis demonstrated the presence of sodium currents, but with partial loss of function. In contrast, six bioinformatics tools for predicting mutational pathogenicity suggested similar impact for all mutations. Likewise, homology modeling of the secondary and tertiary structures failed to reveal misfolding. In conclusion, functional studies using patch clamp are suggested as a prognostic tool, whereby detectable currents imply milder phenotypes and absence of currents indicate an unfavorable prognosis. Future development of automated patch clamp systems will facilitate the inclusion of such functional testing as part of personalized patient diagnostic schemes.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100007353</institution-id>
<institution>Fondation Jérôme Lejeune</institution>
</institution-wrap>
</funding-source>
<award-id>#1565 - 2016b</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-2617-2276</contrib-id>
<name>
<surname>Rubinstein</surname>
<given-names>Moran</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award002">
<funding-source>
<institution>Baharab Foundtion - Tel Aviv University</institution>
</funding-source>
<award-id>2016</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-2617-2276</contrib-id>
<name>
<surname>Rubinstein</surname>
<given-names>Moran</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award003">
<funding-source>
<institution>The Bicher Benner Foundation</institution>
</funding-source>
<principal-award-recipient>
<name>
<surname>Nissenkorn</surname>
<given-names>Andreea</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award004">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100003977</institution-id>
<institution>Israel Science Foundation</institution>
</institution-wrap>
</funding-source>
<award-id>1454/17</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-2617-2276</contrib-id>
<name>
<surname>Rubinstein</surname>
<given-names>Moran</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award005">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001673</institution-id>
<institution>Fondation Jérôme Lejeune</institution>
</institution-wrap>
</funding-source>
<award-id>#1565 - 2016b</award-id>
<principal-award-recipient>
<name>
<surname>Nissenkorn</surname>
<given-names>Andreea</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award006">
<funding-source>
<institution>The Bicher Benner Foundation</institution>
</funding-source>
<principal-award-recipient>
<name>
<surname>Yakubovich</surname>
<given-names>Daniel</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>This study was supported by: 1. The Jérôme Lejeune Foundation grant #1565 - 2016b (AN and MR). This grant covered the costs of cell cultures and electrophysiological recordings. 2. The Bicher Benner Foundation (AN and DY) covered the costs of the molecular biology reagents. 3. The Baharab Foundation - Tel Aviv University 2016 grant (MR) covered part of the costs of the electrophysiological equipment. 4. Israel Science Foundation grant 1- 454/17 (MR) covered part of the costs of the electrophysiological equipment and supported part of the Ph.D. stipend of YA.</funding-statement>
</funding-group>
<counts>
<fig-count count="3"></fig-count>
<table-count count="3"></table-count>
<page-count count="16"></page-count>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the manuscript and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<title>Data Availability</title>
<p>All relevant data are within the manuscript and its Supporting Information files.</p>
</notes>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Dravet syndrome (previously Severe Myoclonic Epilepsy in Infancy, SMEI) is a developmental and epileptic encephalopathy of early childhood with an ominous course [<xref ref-type="bibr" rid="pone.0211901.ref001">1</xref>](<ext-link ext-link-type="uri" xlink:href="http://www.ilea.org">www.ilea.org</ext-link>). Children develop normally during the first months but subsequently exhibit unusually severe febrile convulsions before the age of 12 months. Later, various kinds of drug-resistant seizures appear, with or without myoclonus, tending towards the development of <italic>status epilepticus</italic>, especially during febrile illness. Following the onset of epilepsy, developmental delay becomes evident. Cognition continues to deteriorate and ultimately leads to moderate to severe intellectual disability. In parallel with the cognitive decline, communication skills become impaired and autistic features develop, as well as severe behavioral problems [<xref ref-type="bibr" rid="pone.0211901.ref001">1</xref>, <xref ref-type="bibr" rid="pone.0211901.ref002">2</xref>]. Over 80% of Dravet cases are associated with heterozygous <italic>de novo</italic> mutations in the <italic>SCN1A</italic> gene, which encodes for the alpha subunit of the type I voltage-gated sodium channel (Na<sub>V</sub>1.1), essential for neuronal activity [<xref ref-type="bibr" rid="pone.0211901.ref003">3</xref>].</p>
<p>Prompt and precise diagnosis of Dravet is critical, due to the high risk of <italic>status epilepticus</italic> and sudden unexplained death in epilepsy (SUDEP), and that commonly prescribed antiepileptic sodium channel blockers aggravate Dravet seizures [<xref ref-type="bibr" rid="pone.0211901.ref004">4</xref>]. Hence, in order to address the pressing need for early diagnosis, genetic testing of the <italic>SCN1A</italic> gene is recommended in infants presenting with two or more severe febrile seizures before the age of 12 months [<xref ref-type="bibr" rid="pone.0211901.ref005">5</xref>]. Nevertheless, the interpretation of <italic>SCN1A</italic> genetic analysis is not always trivial.</p>
<p>It has been suggested that the severity of clinical phenotype correlates with the degree of Na<sub>V</sub>1.1 loss-of-function. According to this, severe mutations that result in complete loss of Na<sub>V</sub>1.1 function lead to Dravet syndrome, whereas mutations that only partially reduce Na<sub>V</sub>1.1 activity cause milder phenotypic variants. Included among the latter is GEFS+ (genetic epilepsy with febrile seizure plus), a childhood-onset epilepsy that is well controlled by antiepileptic drugs; and milder forms of Dravet syndrome [<xref ref-type="bibr" rid="pone.0211901.ref006">6</xref>] (<ext-link ext-link-type="uri" xlink:href="http://www.ilae.org">www.ilae.org</ext-link>), which manifest lower seizure burden, higher cognitive abilities and lower risk of <italic>status epilepticus</italic> (previously termed SMEI-borderland, SMEB, or intractable childhood epilepsy with generalized tonic-clonic seizures, ICEGTC) [<xref ref-type="bibr" rid="pone.0211901.ref007">7</xref>, <xref ref-type="bibr" rid="pone.0211901.ref008">8</xref>].</p>
<p>Identification of <italic>de novo SCN1A</italic> nonsense mutations that result in haploinsufficiency allows for immediate Dravet prognosis. However, predicting the damaging effect and clinical significance of <italic>de novo SCN1A</italic> missense mutations is less clear. While roughly half of Dravet patients harbor nonsense mutations, as many as 43% of patients carry <italic>de novo</italic> missense <italic>SCN1A</italic> mutations, leaving prognoses uncertain and families and physicians puzzled [<xref ref-type="bibr" rid="pone.0211901.ref001">1</xref>, <xref ref-type="bibr" rid="pone.0211901.ref009">9</xref>]. Interestingly, in contrast to <italic>de novo SCN1A</italic> mutations, which are the focus of this report, the clinical outcome of inherited <italic>SCN1A</italic> mutations varies even among kin, probably due to the influence of modifier genes [<xref ref-type="bibr" rid="pone.0211901.ref010">10</xref>–<xref ref-type="bibr" rid="pone.0211901.ref012">12</xref>].</p>
<p>To address the diagnostic challenge of <italic>de novo SCN1A</italic> mutation in patients with early seizure onset, we examined the correlations between clinical presentation, functional ramifications of sodium currents and bioinformatics prediction of expected pathogenicity in four <italic>de novo SCN1A</italic> missense mutations. Our data indicate that current bioinformatics tools cannot predict the severity of epilepsy or cognitive outcome. In contrast, functional studies in a mammalian expression system demonstrate a correlation between the degree of Na<sub>V</sub>1.1 loss-of-function, seizure burden and cognitive outcome. Thus, we propose the use of automated patch clamp systems, which provide rapid and technically easier functional analysis, as part of a personalized prognosis and treatment scheme for patients with <italic>de novo SCN1A</italic> missense mutations.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Methods</title>
<sec id="sec003">
<title>Patients</title>
<p>Four patients with Dravet syndrome, treated at our pediatric neurology clinic and found to harbor missense mutations in the <italic>SCN1A</italic> gene, were selected for <italic>in vitro</italic> and <italic>in silico</italic> modeling and functional studies. Clinical diagnosis of Dravet syndrome was made based on: a) severe febrile seizures early in life, b) drug-resistant seizures (with or without myoclonus), and c) cognitive deterioration starting after the second year of life [<xref ref-type="bibr" rid="pone.0211901.ref005">5</xref>].</p>
<p>The following clinical data were extracted from patient charts: age, gender, molecular diagnosis, age at onset of seizures, type of seizures, age at onset of febrile seizures, presence of febrile/afebrile <italic>status epilepticus</italic>, antiepileptic drugs used, type of schooling and control of seizures at three time points: two and five years of age, and most-recent visit. Seizure control was defined as the number of seizures per month (excluding myoclonic seizure and atypical absences). Existing EEG records at ages two and five years (±6 months) were used for spectral analysis of the background activity, as described by Holmes et al, 2012 [<xref ref-type="bibr" rid="pone.0211901.ref013">13</xref>]. Two 30 sec recorded segments, devoid of artifacts or epileptiform discharges, during the awake state (with eyes open) were sampled. Recordings were imported to Matlab 6.5 for Windows (Mathworks Inc. Natick, MA, USA) and digitally lowpass filtered with a cut-off frequency of 40 Hz. Power spectrums were generated utilizing the Welch algorithm. Data between 1 and 40 Hz were subjected to calculation of mean frequencies and power band analysis (α/β/δ/θ percentage).</p>
<p>In contrast to standard developmental assessment, in which assorted IQ or DQ scores are evaluated using different methods, we uniformly administered VABS (Vineland Adaptive Behavior Score- Vineland II) performed during regular visits in our neurology clinic. Standard scores for the complete test and for different domains (communication, daily life, socialization and motor skills), as well as V scores for subdomains and maladaptive behavior index were computed and standardized to age according to the Vineland II manual [<xref ref-type="bibr" rid="pone.0211901.ref014">14</xref>].</p>
<p>The study was approved by the institutional review committee at the Sheba Medical Center (IRB- 4870-18-SMC). Subject or parental informed consent was not required since the data was extracted from patient charts while anonymity of the subjects was protected.</p>
</sec>
<sec id="sec004">
<title>Molecular biology</title>
<p>Human Na<sub>V</sub>1.1 Na<sup>+</sup> channel α subunit (hNa<sub>V</sub>1.1, NM_006920), inserted into pCDM8 vector, was generously provided by Prof. William A. Catterall (University of Washington, Seattle, WA, USA). The plasmid was propagated in TOP10/P3 cells (Invitrogen, Carlsbad, CA, USA) for &gt; 30 h at 30°C, to minimize spontaneous rearrangement. The entire coding sequence was sequenced after each propagation. Point mutations were introduced using Phusion High-Fidelity DNA Polymerase (New England Biolabs, Ipswich, MA, USA) using the following primers: for Na<sub>V</sub>1.1<sup>G177A</sup>
<monospace>5’CTTATAAAAATTATTGCAAGGGCATTCTGTTTAGAAGATTTTACTTTCC and 5’GGAAAGTAAAATCTTCTAAACAGAATGCCCTTGCAATAATTTTTATAAG; for Na<sub>V</sub>1.1<sup>S259R</sup> 5’CTGTGTTCTGTCTGAGAGTATTTGCTCTAATTGGGCTG and 5’CAGCCCAATTAGAGCAAATACTCTCAGACAGAACACAG; for Na<sub>V</sub>1.1<sup>M1267I</sup> 5’ CATTTTCATTCTGGAAATACTTCTAAAATGGGTGGCATATGGC and 5’ GCCATATGCCACCCATTTTAGAAGTATTTCCAGAATGAAAATG; and for Na<sub>V</sub>1.1<sup>Q1923R</sup> 5’ CTGCTGTCATTATTCGGCGTGCTTACAGACGCCACC and 5’ GGTGGCGTCTGTAAGCACGCCGAATAATGACAGCAG</monospace>.</p>
</sec>
<sec id="sec005">
<title>Cell culture and transfections</title>
<p>HEK-293 (ATCC CRL-1573) cells were cultured in Dulbecco’s Modified Eagle Medium supplemented with 10% fetal bovine serum, 10 units/mL penicillin and 10μg/mL streptomycin (Biological Industries, Beit-Haemek, Israel), and grown at 37 °C with 5% CO<sub>2</sub>. For electrophysiological recordings, cells were transiently transfected with cDNAs encoding Na<sub>V</sub>1.1<sup>WT</sup> or mutants (2 μg) and GFP (0.5 μg) in 35mm plates using polyethylenimine (Sigma Aldrich, St. Louis, MO, USA). Recordings were made 2–3 days after transfection. Na<sub>V</sub>1.1<sup>WT</sup> was transfected with each of the mutants, and each recording session started by recording currents from Na<sub>V</sub>1.1<sup>WT</sup> in order to verify normal expression.</p>
<p>For Western blot analysis, cells in 60 mm plates were transfected with 6 μg cDNA of Na<sub>V</sub>1.1<sup>WT</sup> or mutants and cultured for 3 days.</p>
</sec>
<sec id="sec006">
<title>Electrophysiology</title>
<p>Our electrophysiological recordings were performed as described previously [<xref ref-type="bibr" rid="pone.0211901.ref015">15</xref>] with small changes that are indicated below. Recordings were made using an Axopatch 200B amplifier (Molecular Devices, San Jose, CA, USA), or a Sutter IPA (Sutter Instrument, Novato, CA, USA) amplifier. Data were analyzed using Clampfit (Molecular Devices, San Jose, CA, USA) and IGOR Pro (WaveMetrics, Inc., Lake Oswego, OR, USA). For voltage clamp recording the glass pipettes had resistances of 3–5 MΩ. Capacitive currents were minimized using the amplifier circuitry. We routinely used 75–80% series resistance compensation. The remaining linear capacity and leakage currents were eliminated by P/4 subtraction. The pipette solutions contained (in mM): 140 CsF, 10 NaCl, 1 EGTA, 10 HEPES, 10 glucose, adjusted to pH 7.3 with CsOH. The external solution contained (in mM): 140 NaCl, 20 glucose, 10 HEPES, 1 MgCl<sub>2</sub>, 3 KCl, 1 CaCl<sub>2</sub>, adjusted to pH 7.35 with NaOH. Chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) or Fisher Chemical (Waltham, MA USA). The voltage dependence of activation was measured from a holding potential of -120 mV. Cells were depolarized for 20 ms to potentials ranging from -70 to +40 mV in 10 mV increments, and peak inward currents were measured. Conductance (G)-voltage relationships were determined from peak current (I) versus voltage relationships as G = I/(V—V<sub>Rev</sub>), where V was the test potential and V<sub>Rev</sub> was the extrapolated reversal potential. The voltage dependence of inactivation was measured from a holding potential of -120 mV. Cells were depolarized for 500 ms to potentials ranging from -90 to +50 mV in 10 mV increments, followed by test pulses to -10 mV. Recovery from inactivation was examined by applying a 20 ms conditioning pulse to 0 mV from a holding potential of -120 mV, followed by a recovery interval of variable duration (Δ1 ms) and a test pulse to 0 mV. To examine Na<sub>V</sub>1.1 channel availability, repetitive depolarizations to 0 mV (2 ms long), at 50 Hz, from a holding potential of -70mV, were used.</p>
<p>We attempted a rescue of the function of Na<sub>V</sub>1.1 mutants by applying the specific Na<sub>V</sub>1.1 opener, Hm1a (250 nM) [<xref ref-type="bibr" rid="pone.0211901.ref016">16</xref>], or by pharmacological chaperoning using the Na<sub>V</sub>1.1 modulator N,N'-(1,3-phenylene)bis(2-methylbenzamide), also known as Na<sub>V</sub>1.1-Compound 3a [<xref ref-type="bibr" rid="pone.0211901.ref017">17</xref>]. Na<sub>V</sub>1.1-Compound 3a was shown to increase the firing of fast-spiking interneurons in brain slices and its calculated partition coefficient (clogP of 3.48) is expected to support membrane permeability [<xref ref-type="bibr" rid="pone.0211901.ref017">17</xref>]. Cells were incubated 48–72 h with Na<sub>V</sub>1.1-Compound 3a (30 μM), but the drug was washed out prior to recording to prevent a reduction in peak amplitude.</p>
<p>Hm1a and Na<sub>V</sub>1.1-Compound 3a were purchased from Alomone Labs (Jerusalem, Israel; catalog numbers STH-601 and CMN-002, respectively).</p>
</sec>
<sec id="sec007">
<title>Western blot</title>
<p>Cells were homogenized in 0.32M sucrose supplemented with protease inhibitors (Sigma-Aldrich, St. Louis, MO, USA), 1mM EDTA and 1mM PMSF, pH 7.4. Crude membrane preparation was produced by centrifugation at 17,000 x g for 90 min. The precipitate (pellet) was solubilized in 150 mM NaCl, 2% Triton X-100 supplemented with protease inhibitors, 1mM EDTA and 1mM PMSF, pH 7.4. A 35 mg aliquot of total protein was separated on Tris-acetate gel (6%) and transferred onto PVDF membrane. After blocking with 5% w/v nonfat dry milk in TBST, the membrane was incubated with anti-Na<sub>V</sub>1.1 antibody (1:200, Alomone Labs, Jerusalem, Israel; catalog number ASC-001) or Alpha 1 Na<sup>+</sup>/K<sup>+</sup> ATPase (1:200, Alomone Labs, Jerusalem, Israel; catalog number ANP-001), followed by incubation with HRP-conjugated goat anti-rabbit antibody (1:10,000, Sigma-Aldrich, St. Louis, MO, USA). The signal was visualized by chemiluminescent detection using the ECL Detection System.</p>
</sec>
<sec id="sec008">
<title>Statistical analysis</title>
<p>The data are expressed as mean ± standard error. Normality was tested using the Shapiro-Wilk’s W test. Equal variance was confirmed using the Levene’s test followed by two-tailed Student’s t-test or repeated measures ANOVA, as appropriate. SigmaPlot 12.5 (Systat Software, London, UK) was utilized to calculate statistical measures.</p>
</sec>
<sec id="sec009">
<title>Bioinformatics assessment of the significance of <italic>SCN1A</italic> missense mutations</title>
<p>The effects of the nonsynonymous amino acid change in the four mutations was predicted using 5 bioinformatics tools: SIFT (Sorting Intolerant From Tolerant algorithm) [<xref ref-type="bibr" rid="pone.0211901.ref018">18</xref>] (<ext-link ext-link-type="uri" xlink:href="http://sift.jcvi.org">http://sift.jcvi.org</ext-link>), MutationAssessor [<xref ref-type="bibr" rid="pone.0211901.ref019">19</xref>] (<ext-link ext-link-type="uri" xlink:href="http://mutationassessor.org">http://mutationassessor.org</ext-link>), PolyPhen-2 (Polymorphism Phenotyping v2) [<xref ref-type="bibr" rid="pone.0211901.ref020">20</xref>] (<ext-link ext-link-type="uri" xlink:href="http://genetics.bwh.harvard.edu/pph2">http://genetics.bwh.harvard.edu/pph2</ext-link>), Condel (CONsensus DELeteriousness score) [<xref ref-type="bibr" rid="pone.0211901.ref021">21</xref>] (<ext-link ext-link-type="uri" xlink:href="http://bbglab.irbbarcelona.org/fannsdb">http://bbglab.irbbarcelona.org/fannsdb</ext-link>), and PROVEAN (Protein Variation Effect Analyzer) [<xref ref-type="bibr" rid="pone.0211901.ref022">22</xref>] (<ext-link ext-link-type="uri" xlink:href="http://provean.jcvi.org">http://provean.jcvi.org</ext-link>). In addition, we assessed the pathogenicity of seven control mutations, previously described as causing either Dravet, GEFS+ or febrile seizures [<xref ref-type="bibr" rid="pone.0211901.ref023">23</xref>, <xref ref-type="bibr" rid="pone.0211901.ref024">24</xref>].</p>
<p>Mutations with a score over the threshold for each bioinformatics tool were considered pathogenic. For MutationAssessor [<xref ref-type="bibr" rid="pone.0211901.ref019">19</xref>], a higher score predicts a more severe mutation (<ext-link ext-link-type="uri" xlink:href="http://mutationassessor.org">http://mutationassessor.org</ext-link>). Regarding the other assessment tools, a higher score means a greater probability that the prediction of pathogenicity is accurate.</p>
<p>Homology modeling was performed by submitting mutant and wild-type sequences to the SWISS-MODEL Workspace (<ext-link ext-link-type="uri" xlink:href="https://swissmodel.expasy.org">https://swissmodel.expasy.org</ext-link>). The following templates from the PDB repository (<ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/pdb">https://www.rcsb.org/pdb</ext-link>) were used for alignment: 4dck1.a (Na<sub>V</sub>1.5) for C terminal mutation and 5xsy.1.A (Na<sub>V</sub>1.2) for the other mutations. Information regarding Na<sub>V</sub>1.1 protein (UniProtKB—P35498) domains and secondary structures were extrapolated from the UniProt Knowledgebase (<ext-link ext-link-type="uri" xlink:href="http://uniprot.org">http://uniprot.org</ext-link>).</p>
</sec>
</sec>
<sec id="sec010" sec-type="results">
<title>Results</title>
<sec id="sec011">
<title>Patients</title>
<p>Four patients (2 male, 2 female), 5.3–10.8 years of age (mean 8.1), harboring the following <italic>de novo</italic> mutations in the <italic>SCN1A</italic> gene: p.Gly177Ala, p.Ser.259Arg, p.Met1267Ile, and p.Glu1923Arg, were enrolled in this study (<xref ref-type="table" rid="pone.0211901.t001">Table 1</xref>). The locations of these mutations are depicted in <xref ref-type="fig" rid="pone.0211901.g001">Fig 1</xref>. The p.Gly177Ala mutation is located within the cytoplasm-facing loop, connecting the S2-S3 segments of the first domain. The p.Ser259Arg and p.Met1267Ile mutations are in the transmembrane domain, within S5 (domain I) and S2 (domain III), respectively. The p.Glu1923Arg mutation is positioned within the intracellular C-terminal domain (<xref ref-type="fig" rid="pone.0211901.g001">Fig 1</xref>).</p>
<fig id="pone.0211901.g001" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0211901.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Topology diagram of <italic>SCN1A</italic> missense mutations.</title>
<p>Topology diagram of Na<sub>V</sub>1.1 illustrating the location and amino acid substitution of the studied <italic>SCN1A</italic> missense mutations.</p>
</caption>
<graphic xlink:href="pone.0211901.g001"></graphic>
</fig>
<table-wrap id="pone.0211901.t001" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0211901.t001</object-id>
<label>Table 1</label>
<caption>
<title>Clinical characteristics of patients.</title>
</caption>
<alternatives>
<graphic id="pone.0211901.t001g" xlink:href="pone.0211901.t001"></graphic>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center" colspan="1" rowspan="1">Mutation</th>
<th align="center" colspan="1" rowspan="1">p.Gly177Ala</th>
<th align="center" colspan="1" rowspan="1">p.Ser259Arg</th>
<th align="center" colspan="1" rowspan="1">p.Met1267Ile</th>
<th align="center" colspan="1" rowspan="1">p.Glu1923Arg</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>Age (years)</bold>
</td>
<td align="center" colspan="1" rowspan="1">6.9</td>
<td align="center" colspan="1" rowspan="1">5.3</td>
<td align="center" colspan="1" rowspan="1">10.8</td>
<td align="center" colspan="1" rowspan="1">9.5</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>Gender</bold>
</td>
<td align="center" colspan="1" rowspan="1">male</td>
<td align="center" colspan="1" rowspan="1">female</td>
<td align="center" colspan="1" rowspan="1">female</td>
<td align="center" colspan="1" rowspan="1">male</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>Age at onset of febrile seizures</bold>
<break></break>
<bold>(month)</bold>
</td>
<td align="center" colspan="1" rowspan="1">6</td>
<td align="center" colspan="1" rowspan="1">5</td>
<td align="center" colspan="1" rowspan="1">4</td>
<td align="center" colspan="1" rowspan="1">7</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>Age at onset of afebrile seizures</bold>
<break></break>
<bold>(month)</bold>
</td>
<td align="center" colspan="1" rowspan="1">12</td>
<td align="center" colspan="1" rowspan="1">12</td>
<td align="center" colspan="1" rowspan="1">12</td>
<td align="center" colspan="1" rowspan="1">5</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>Myoclonic seizures</bold>
</td>
<td align="center" colspan="1" rowspan="1">no</td>
<td align="center" colspan="1" rowspan="1">yes</td>
<td align="center" colspan="1" rowspan="1">no</td>
<td align="center" colspan="1" rowspan="1">yes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>Status epilepticus</bold>
</td>
<td align="center" colspan="1" rowspan="1">yes<xref ref-type="table-fn" rid="t001fn001">*</xref></td>
<td align="center" colspan="1" rowspan="1">yes</td>
<td align="center" colspan="1" rowspan="1">yes</td>
<td align="center" colspan="1" rowspan="1">yes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>Seizure frequency, age 2 years</bold>
<break></break>
<bold>(seizures/month)</bold>
</td>
<td align="center" colspan="1" rowspan="1">1</td>
<td align="center" colspan="1" rowspan="1">0.5</td>
<td align="center" colspan="1" rowspan="1">0.5</td>
<td align="center" colspan="1" rowspan="1">10</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>Seizure frequency, age 5 years</bold>
<break></break>
<bold>(seizures/month)</bold>
</td>
<td align="center" colspan="1" rowspan="1">2</td>
<td align="center" colspan="1" rowspan="1">2</td>
<td align="center" colspan="1" rowspan="1">1</td>
<td align="center" colspan="1" rowspan="1">5</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>Seizure frequency, last visit</bold>
<break></break>
<bold>(seizures/month)</bold>
</td>
<td align="center" colspan="1" rowspan="1">1</td>
<td align="center" colspan="1" rowspan="1">2</td>
<td align="center" colspan="1" rowspan="1">0.25</td>
<td align="center" colspan="1" rowspan="1">8</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>Antiepileptic treatment</bold>
<break></break>
<bold>(last visit)</bold>
</td>
<td align="center" colspan="1" rowspan="1">VPA, CLB, CBD</td>
<td align="center" colspan="1" rowspan="1">VPA, CLB, CBD, VNS</td>
<td align="center" colspan="1" rowspan="1">VPA, CLN, STR</td>
<td align="center" colspan="1" rowspan="1">VPA, CLB, CBD</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001">
<p>*Patient developed severe hypoxic ischemic encephalopathy with left parieto-occipital stroke after prolonged <italic>status epilepticus</italic></p>
</fn>
<fn id="t001fn002">
<p>VPA- valproic acid, CLB-clobazam, CLN- clonazepam, STR-stiripentol, CBD- cannabidiol enriched medical marijuana, VNS- vagal nerve stimulator</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>All patients had severe early febrile seizures, with recurrent febrile and non-febrile <italic>status epilepticus</italic>; one patient (p.Gly177Ala) developed a hypoxic ischemic event with cerebellar stroke and prolonged encephalopathy during <italic>status epilepticus</italic>. Seizure burden differed at 2 years of age, and in particular at 5 years of age (<xref ref-type="table" rid="pone.0211901.t001">Table 1</xref>). A polytherapy regime which included valproic acid and benzodiazepines was used to treat all patients, while three of the patients were also treated with cannabidiol-enriched (CBD 30%) medical marijuana, according to CBD 10 mg/kg/day.</p>
<p>Three patients (p.Gly177Ala, p.Ser259Arg and p.Met1267Ile) had electroencephalography (EEG) recordings at around two and five years of age, suitable for background analysis during the awake state. The mean background frequencies and power band measured in left frontal F3 electrodes are presented in <xref ref-type="supplementary-material" rid="pone.0211901.s001">S1 Table</xref>. Though this sample size is insufficient for adequate statistical analysis, p.Met1276Ile shows less slowing of background at 2 as well as at 5 years of age, as depicted by higher mean frequency and higher beta power (<xref ref-type="supplementary-material" rid="pone.0211901.s001">S1 Table</xref>), compared to the other mutations.</p>
<p>All patients were evaluated with Vineland Adaptive Behavior Scale (VABS), which enables the comparison of patient performance at different ages (<xref ref-type="table" rid="pone.0211901.t002">Table 2</xref>). While the patient carrying the p.Met1267Ile mutation scored within normal borderline range, the other patients performed within the low range (<xref ref-type="table" rid="pone.0211901.t002">Table 2</xref>). Interestingly, patients carrying the p.Met1267Ile or p.Ser259Arg mutations performed highest in the communication domain, especially in the receptive language subdomain, in which they were within normal range (V = 13, 13–17 = adequate). Nevertheless, they performed discordantly low in daily living skills (<xref ref-type="table" rid="pone.0211901.t002">Table 2</xref>). Finally, the patient carrying the p.Met1267Ile mutation attends a regular mainstream school with the help of a personal assistant, while the three other children are enrolled in special schooling programs.</p>
<table-wrap id="pone.0211901.t002" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0211901.t002</object-id>
<label>Table 2</label>
<caption>
<title>Vineland Adaptive Behavior Score (VABS) in patients.</title>
</caption>
<alternatives>
<graphic id="pone.0211901.t002g" xlink:href="pone.0211901.t002"></graphic>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="2" rowspan="1">Mutation</th>
<th align="center" colspan="1" rowspan="1">p.Gly177Ala</th>
<th align="center" colspan="1" rowspan="1">p.Ser259Arg</th>
<th align="center" colspan="1" rowspan="1">p.Met1267Ile</th>
<th align="center" colspan="1" rowspan="1">p.Glu1923Arg</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="2" rowspan="1">
<bold>Age at test (years)</bold>
</td>
<td align="center" colspan="1" rowspan="1">6.9</td>
<td align="center" colspan="1" rowspan="1">5.3</td>
<td align="center" colspan="1" rowspan="1">10.8</td>
<td align="center" colspan="1" rowspan="1">8.5</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1">
<bold>VABS Standard score</bold>
<xref ref-type="table-fn" rid="t002fn001">*</xref>
<break></break>
<bold>(z score)</bold>
</td>
<td align="center" colspan="1" rowspan="1">56 (0.2%)</td>
<td align="center" colspan="1" rowspan="1">65 (1%)</td>
<td align="center" colspan="1" rowspan="1">71 (3%)</td>
<td align="center" colspan="1" rowspan="1">56 (0.2%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="4">
<bold>Subdomain</bold>
<break></break>
<bold>Standard Score</bold>
<xref ref-type="table-fn" rid="t002fn001">*</xref>
<break></break>
<bold>(z score)</bold>
</td>
<td align="left" colspan="1" rowspan="1">
<bold>Communication</bold>
</td>
<td align="center" colspan="1" rowspan="1">57 (0.2%)</td>
<td align="center" colspan="1" rowspan="1">78 (7%)</td>
<td align="center" colspan="1" rowspan="1">79 (8%)</td>
<td align="center" colspan="1" rowspan="1">56 (0.2%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>Daily living skills</bold>
</td>
<td align="center" colspan="1" rowspan="1">53 (0.1%)</td>
<td align="center" colspan="1" rowspan="1">53 (0.1%)</td>
<td align="center" colspan="1" rowspan="1">64 (1%)</td>
<td align="center" colspan="1" rowspan="1">57 (0.2%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>Socialization</bold>
</td>
<td align="center" colspan="1" rowspan="1">65 (1%)</td>
<td align="center" colspan="1" rowspan="1">70 (2%)</td>
<td align="center" colspan="1" rowspan="1">76 (5%)</td>
<td align="center" colspan="1" rowspan="1">53 (0.1%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>Motor skills</bold>
</td>
<td align="center" colspan="1" rowspan="1">61 (1%)</td>
<td align="center" colspan="1" rowspan="1">67 (1%)</td>
<td align="center" colspan="1" rowspan="1">76 (5%)</td>
<td align="center" colspan="1" rowspan="1">54 (0.1%)</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1">
<bold>Maladaptive behavior index</bold>
<xref ref-type="table-fn" rid="t002fn002">**</xref>
</td>
<td align="center" colspan="1" rowspan="1">21</td>
<td align="center" colspan="1" rowspan="1">17</td>
<td align="center" colspan="1" rowspan="1">20</td>
<td align="center" colspan="1" rowspan="1">22</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001">
<p>*Adaptive levels according to Standard Score: Low 20–70; Moderately low 71–85; Adequate 86–114; Moderately high 115–129; High 130–160.</p>
</fn>
<fn id="t002fn002">
<p>** Maladaptive behavior index: Clinically significant 21–24; Elevated 18–20; Average 1–17.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec012">
<title>Biophysical characterization of missense <italic>SCN1A</italic> mutations</title>
<p>In order to characterize the biophysical ramifications of missense <italic>SCN1A</italic> mutations, we transiently transfected wild-type (WT) and mutant Na<sub>V</sub>1.1 channels into heterologous human HEK-293 cells. The resulting sodium currents were measured using whole-cell voltage clamp. Three of the four missense mutations, p.Gly177Ala, p.Ser259Arg and p.Glu1923Arg, failed to produce detectable sodium currents, suggesting a complete loss of function (<xref ref-type="fig" rid="pone.0211901.g002">Fig 2</xref>). We attempted a rescue of function by applying the specific Na<sub>V</sub>1.1 opener, Hm1a [<xref ref-type="bibr" rid="pone.0211901.ref016">16</xref>]. However, while Hm1a increased the amplitude of Na<sub>V</sub>1.1<sup>WT</sup> channels by 16.8 ± 6.44%, and reduced the inactivation by 28.4 ± 3.57% (<xref ref-type="supplementary-material" rid="pone.0211901.s002">S1 Fig</xref>), there was no rescue of function for p.Gly177Ala, p.Ser259Arg or p.Glu1923Arg mutations (<xref ref-type="supplementary-material" rid="pone.0211901.s002">S1 Fig</xref>).</p>
<fig id="pone.0211901.g002" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0211901.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Complete loss of function in missense <italic>SCN1A</italic> mutations.</title>
<p>(A) Representative set of sodium current traces from HEK-293 cells expressing Na<sub>V</sub>1.1<sup>WT</sup>, Na<sub>V</sub>1.1<sup>G177A</sup>, Na<sub>V</sub>1.1<sup>S259R</sup> or Na<sub>V</sub>1.1<sup>Q1923R</sup>. (B) Mean current-voltage (I-V) relationships of sodium current densities. Na<sub>V</sub>1.1<sup>WT</sup> n = 31; Na<sub>V</sub>1.1<sup>G177A</sup> n = 10; Na<sub>V</sub>1.1<sup>S259R</sup> n = 7; Na<sub>V</sub>1.1<sup>Q1923R</sup> n = 7.</p>
</caption>
<graphic xlink:href="pone.0211901.g002"></graphic>
</fig>
<p>We further examined the membrane expression of Na<sub>V</sub>1.1 channels in crude membrane preparation using western blot (<xref ref-type="supplementary-material" rid="pone.0211901.s003">S2 Fig</xref>). The expression of the p.Gly177Ala was reduced, potentially indicating defects in protein synthesis, trafficking or stability, while the expression of the other mutants was comparable to that of Na<sub>V</sub>1.1<sup>WT</sup> (<xref ref-type="supplementary-material" rid="pone.0211901.s003">S2 Fig</xref>). Our membrane preparation does not differentiate between the plasma membrane and other cellular membranes, including those of the endoplasmic reticulum. Thus, with or without Hm1a, the absence of currents (<xref ref-type="fig" rid="pone.0211901.g002">Fig 2</xref> and <xref ref-type="supplementary-material" rid="pone.0211901.s002">S1 Fig</xref>) may be a result of defective trafficking, defective gating or both.</p>
<p>We further evaluated the effect of a pharmacological chaperoning by incubating the transfected cells with Na<sub>V</sub>1.1-Compound 3a, which is a modulator of Na<sub>V</sub>1.1 activity [<xref ref-type="bibr" rid="pone.0211901.ref017">17</xref>]. Under these conditions, we were able to record small currents in some cells (<xref ref-type="supplementary-material" rid="pone.0211901.s004">S3A Fig</xref>), but the rescue was still minimal (<xref ref-type="supplementary-material" rid="pone.0211901.s004">S3 Fig</xref>).</p>
<p>In contrast, expression of the p.Met1267Ile mutation resulted in sodium currents that were similar in amplitude to Na<sub>V</sub>1.1<sup>WT</sup> without normalization of cell capacitance (<xref ref-type="supplementary-material" rid="pone.0211901.s005">S4A Fig</xref>), but reduced after this normalization (<xref ref-type="fig" rid="pone.0211901.g003">Fig 3A and 3B</xref>). Persistent sodium currents, measured at the end of the 20 ms depolarization, were not statistically different between Na<sub>V</sub>1.1<sup>WT</sup> and Na<sub>V</sub>1.1<sup>M1267I</sup> (<xref ref-type="supplementary-material" rid="pone.0211901.s005">S4B Fig</xref>). There was a shift toward hyperpolarization in the voltage dependency of activation (<xref ref-type="fig" rid="pone.0211901.g003">Fig 3C</xref>), and a marked slowing of the recovery from fast inactivation (<xref ref-type="fig" rid="pone.0211901.g003">Fig 3D</xref>). Moreover, while the amplitude of Na<sub>V</sub>1.1<sup>WT</sup> channels declined by ~20% during repetitive depolarizations at 50 Hz, the reduction in channel availability was doubled in the Na<sub>V</sub>1.1<sup>M1267I</sup> (<xref ref-type="fig" rid="pone.0211901.g003">Fig 3E</xref>). Together, our functional data indicate that the p.Met1267Ile mutation confers partial loss of function effect. Nevertheless, similarly to the effect on Na<sub>V</sub>1.1<sup>WT</sup>, application of the Hm1a toxin increased the peak currents of Na<sub>V</sub>1.1<sup>M1267I</sup> by 21.13 ± 8% and reduced its inactivation by 21.2 ± 7% (<xref ref-type="supplementary-material" rid="pone.0211901.s002">S1 Fig</xref>).</p>
<fig id="pone.0211901.g003" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0211901.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Partial loss of function in the p.Met1269Ile mutations.</title>
<p>(A) Representative sodium current traces from HEK-293 expressing Na<sub>V</sub>1.1<sup>WT</sup> or Na<sub>V</sub>1.1<sup>M1267I</sup>. (B) Mean current-voltage (I–V) relationships of current densities. (C) Voltage dependence of activation (right curves: V<sub>1/2</sub> of -24.1 ± 1.5 mV for Na<sub>V</sub>1.1<sup>WT</sup> and -31.4 ± 1.3 mV for Na<sub>V</sub>1.1<sup>M1267I</sup>, p &lt; 0.01; Na<sub>V</sub>1.1<sup>WT</sup> n = 31; Na<sub>V</sub>1.1<sup>M1267I</sup> n = 16) or the voltage dependence for steady-state fast inactivation (left curves, V<sub>1/2</sub> of -63.6 ± 2 mV for Na<sub>V</sub>1.1<sup>WT</sup> and -65.2 ± 2.5 mV, for Na<sub>V</sub>1.1<sup>M1267I</sup> p &gt; 0.05; Na<sub>V</sub>1.1<sup>WT</sup> n = 26; Na<sub>V</sub>1.1<sup>M1267I</sup> n = 15). (D) Recovery from fast inactivation (Na<sub>V</sub>1.1<sup>WT</sup> n = 8; Na<sub>V</sub>1.1<sup>M1267I</sup> n = 7). (E) Normalized currents during 10 depolarizations from -70 mV to 0 mV at 50 Hz (Na<sub>V</sub>1.1<sup>WT</sup> n = 9; Na<sub>V</sub>1.1<sup>M1267I</sup> n = 9).</p>
</caption>
<graphic xlink:href="pone.0211901.g003"></graphic>
</fig>
<p>Together, our functional analyses revealed complete loss of function in the p.Gly177Ala, p.Ser259Arg and p.Glu1923Arg mutations, while the p.Met1267Ile mutation demonstrated a partial loss of function.</p>
</sec>
<sec id="sec013">
<title>Bioinformatics assessment of pathogenicity of <italic>SCN1A</italic> mutations</title>
<p>The predicted outcome of these mutations was further analyzed using five bioinformatics tools (<xref ref-type="table" rid="pone.0211901.t003">Table 3</xref>). While all four mutations were predicted to be damaging, the predicted scores with SIFT, PolyPhen-2 and Condel were similar for all four mutations. PROVEAN scores were inconsistent (<xref ref-type="table" rid="pone.0211901.t003">Table 3</xref>). In contrast, MutationAssessor predicted a lower impact on protein function for the p.Met1267Ile mutation compared to the three other mutations (<xref ref-type="table" rid="pone.0211901.t003">Table 3</xref>). To further examine the ability of MutationAssessor to correctly predict the outcome of <italic>SCN1A</italic> mutations, we tested additional missense mutations [<xref ref-type="bibr" rid="pone.0211901.ref023">23</xref>, <xref ref-type="bibr" rid="pone.0211901.ref024">24</xref>] (<xref ref-type="table" rid="pone.0211901.t003">Table 3</xref>). This resulted in a lack of correlation between the predicted dampening effect and the clinical severity (<xref ref-type="table" rid="pone.0211901.t003">Table 3</xref>).</p>
<table-wrap id="pone.0211901.t003" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0211901.t003</object-id>
<label>Table 3</label>
<caption>
<title>Prediction of mutation impact according to bioinformatics tools in patients and controls.</title>
</caption>
<alternatives>
<graphic id="pone.0211901.t003g" xlink:href="pone.0211901.t003"></graphic>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="1"></th>
<th align="left" colspan="1" rowspan="1">G177A<break></break>Dravet</th>
<th align="left" colspan="1" rowspan="1">S259R<break></break>Dravet</th>
<th align="left" colspan="1" rowspan="1">M1267I<break></break>Dravet</th>
<th align="left" colspan="1" rowspan="1">Q1923R<break></break>Dravet</th>
<th align="left" colspan="1" rowspan="1">R859C<break></break>GEFS+Dravet</th>
<th align="left" colspan="1" rowspan="1">W1204R<break></break>GEFS+<break></break>Dravet</th>
<th align="left" colspan="1" rowspan="1">V1336I<break></break>GEFS+<break></break>Dravet</th>
<th align="left" colspan="1" rowspan="1">M1664K<break></break>GEFS+<break></break>Dravet</th>
<th align="left" colspan="1" rowspan="1">Y790C<break></break>GEFS+</th>
<th align="left" colspan="1" rowspan="1">M145T<break></break>FS</th>
<th align="left" colspan="1" rowspan="1">M956T<break></break>FS</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>SIFT</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>0</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>0</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>0</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>0</bold>
</td>
<td align="center" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>PolyPhen-2</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>0.99</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>0.99</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>0.99</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>0.99</bold>
</td>
<td align="center" colspan="1" rowspan="1">0.99</td>
<td align="center" colspan="1" rowspan="1">0.99</td>
<td align="center" colspan="1" rowspan="1">0.99</td>
<td align="center" colspan="1" rowspan="1">0.99</td>
<td align="center" colspan="1" rowspan="1">0.97</td>
<td align="center" colspan="1" rowspan="1">0.91</td>
<td align="center" colspan="1" rowspan="1">0.99</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>Mutation Assessor</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>3.975</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>3.505</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>2.4</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>3.56</bold>
</td>
<td align="center" colspan="1" rowspan="1">4.44</td>
<td align="center" colspan="1" rowspan="1">3.76</td>
<td align="center" colspan="1" rowspan="1">3.30</td>
<td align="center" colspan="1" rowspan="1">3.12</td>
<td align="center" colspan="1" rowspan="1">3.58</td>
<td align="center" colspan="1" rowspan="1">3.53</td>
<td align="center" colspan="1" rowspan="1">3.41</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>Condel</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>0.72</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>0.68</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>0.6</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>0.68</bold>
</td>
<td align="center" colspan="1" rowspan="1">0.75</td>
<td align="center" colspan="1" rowspan="1">0.71</td>
<td align="center" colspan="1" rowspan="1">0.67</td>
<td align="center" colspan="1" rowspan="1">0.66</td>
<td align="center" colspan="1" rowspan="1">0.69</td>
<td align="center" colspan="1" rowspan="1">0.68</td>
<td align="center" colspan="1" rowspan="1">0.67</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:thick">
<bold>PROVEAN</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:thick">
<bold>-5.77</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:thick">
<bold>-4.88</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:thick">
<bold>-2.73</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:thick">
<bold>-3.68</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:thick">-7.34</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:thick">-13.37</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:thick">-0.95<xref ref-type="table-fn" rid="t003fn003">**</xref></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:thick">-5.22</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:thick">-8.09</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:thick">-5.48</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:thick">-5.80</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>Significance</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>Damaging</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>Damaging</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>Damaging</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>Damaging</bold>
</td>
<td align="center" colspan="1" rowspan="1">Damaging</td>
<td align="center" colspan="1" rowspan="1">Damaging</td>
<td align="center" colspan="1" rowspan="1">Damaging<xref ref-type="table-fn" rid="t003fn003">**</xref></td>
<td align="center" colspan="1" rowspan="1">Damaging</td>
<td align="center" colspan="1" rowspan="1">Damaging</td>
<td align="center" colspan="1" rowspan="1">Damaging</td>
<td align="center" colspan="1" rowspan="1">Damaging</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t003fn001">
<p>In bold, <italic>SCN1A</italic> mutations that were studied here, GEFS+ genetic epilepsy with febrile seizures plus, FS-febrile seizures.</p>
</fn>
<fn id="t003fn002">
<p>SIFT [<xref ref-type="bibr" rid="pone.0211901.ref018">18</xref>], threshold for pathogenic mutation ≤ 0.05 damaging; PolyPhen-2 [<xref ref-type="bibr" rid="pone.0211901.ref020">20</xref>], &gt; 0.85 probably damaging; Mutation Assessor [<xref ref-type="bibr" rid="pone.0211901.ref019">19</xref>], 0.8–1.9 low impact, 1.9–3.5 medium impact, &gt; 3.5 high impact; Condel [<xref ref-type="bibr" rid="pone.0211901.ref021">21</xref>], &gt;0.469 deleterious; PROVEAN [<xref ref-type="bibr" rid="pone.0211901.ref022">22</xref>], &lt; -2.5 deleterious</p>
</fn>
<fn id="t003fn003">
<p>** V1336I mutations neutral/tolerated in PROVEAN but damaging in other tools</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Moreover, homology modeling failed to reveal any derangement in secondary or tertiary structure in all mutants vs. wild-type protein (<xref ref-type="supplementary-material" rid="pone.0211901.s006">S5 Fig</xref>). Thus, current bioinformatics servers are unable to predict the functional or clinical outcome of <italic>SCN1A</italic> missense mutations.</p>
</sec>
</sec>
<sec id="sec014" sec-type="conclusions">
<title>Discussion</title>
<p>The incidence of Dravet Syndrome is 1 in 16,000 births [<xref ref-type="bibr" rid="pone.0211901.ref025">25</xref>], with most cases attributable to <italic>de novo SCN1A</italic> mutations. With today’s routine use of genetic analysis, <italic>SCN1A</italic> mutations are usually detected by the end of the first year of life [<xref ref-type="bibr" rid="pone.0211901.ref005">5</xref>]. Nevertheless, the clinical outcome of <italic>SCN1A</italic> missense mutations is difficult to predict, as these <italic>de novo</italic> mutations can also lead to milder forms of epilepsy [<xref ref-type="bibr" rid="pone.0211901.ref026">26</xref>]. In this study, we correlated the clinical presentation, biophysical significance and bioinformatics prediction of four <italic>de novo SCN1A</italic> missense mutations. Notably, while multiple modes of bioinformatics analysis failed to predict the severity of the mutation, sodium current recordings, acquired using patch clamp analysis in a mammalian expression system, demonstrated a correlation between the degree of Na<sub>V</sub>1.1 loss of function, seizure burden and adaptive abilities.</p>
<sec id="sec015">
<title>Prompt and correct diagnosis of Dravet is critical</title>
<p>Correct and prompt diagnosis is critical, allowing the establishment of early treatment with appropriate anti-seizure medication, as well as aggressive rescue plans in episodes of <italic>status epilepticus</italic> [<xref ref-type="bibr" rid="pone.0211901.ref005">5</xref>]. To facilitate this, sequencing of the <italic>SCN1A</italic> gene is recommended in children with a clinical picture suggestive of Dravet syndrome [<xref ref-type="bibr" rid="pone.0211901.ref005">5</xref>, <xref ref-type="bibr" rid="pone.0211901.ref027">27</xref>]. While the degree of Na<sub>V</sub>1.1 loss of function is considered correlative with the severity of clinical phenotype [<xref ref-type="bibr" rid="pone.0211901.ref006">6</xref>, <xref ref-type="bibr" rid="pone.0211901.ref026">26</xref>], prognosis in <italic>de novo</italic> missense <italic>SCN1A</italic> mutations generally awaits the presentation of developmental delay due to the challenges remaining in correctly foretelling the functional outcome of these mutations.</p>
<p>Recent literature reports that the age of onset of seizures is a reliable prognostic factor that can differentiate between Dravet and GEFS+ [<xref ref-type="bibr" rid="pone.0211901.ref028">28</xref>]. However, this predictor cannot be used to differentiate between severe and milder Dravet cases. Our patients similarly presented febrile seizure before the age of 12 months. Yet, the patient with the p.Met1267Ile mutation had milder disease outcome, demonstrated by better pharmacological control of seizures, faster EEG background and adaptive function within normal borderline range. Thus, additional predictors are needed.</p>
</sec>
<sec id="sec016">
<title>Current bioinformatics tools fail to predict clinical severity</title>
<p>Bioinformatics tools and servers are widely used to predict the significance of mutations in various genes. In this study, we compared six available bioinformatics tools that are routinely used in predicting disease outcome (<xref ref-type="table" rid="pone.0211901.t003">Table 3</xref> and <xref ref-type="supplementary-material" rid="pone.0211901.s006">S5 Fig</xref>). While all of the mutations were suggested to be pathogenic, none of these tools differentiated between the milder p.Met1267Ile mutation and the other, more severe mutations. Furthermore, these servers were unable to distinguish between Dravet mutations, febrile seizures and GEFS+ mutations (<xref ref-type="table" rid="pone.0211901.t003">Table 3</xref>).</p>
<p>These servers, including SIFT [<xref ref-type="bibr" rid="pone.0211901.ref018">18</xref>], PolyPhen-2 [<xref ref-type="bibr" rid="pone.0211901.ref020">20</xref>], Condel [<xref ref-type="bibr" rid="pone.0211901.ref021">21</xref>] and PROVEAN [<xref ref-type="bibr" rid="pone.0211901.ref022">22</xref>], calculate the probability that a missense mutation will be pathogenic, rather than specify the impact on protein function. It is therefore not surprising that predicting the clinical outcome lies outside of their reach. In contrast, MutationAssessor [<xref ref-type="bibr" rid="pone.0211901.ref019">19</xref>] analyzes the functional effect of a mutation, and thus was assessed for its ability to predict the functional severity of the mutations. This tool was originally designed to predict the impact of cancer-inducing genes rather than membrane-expressed ion channels, and it too failed to differentiate between mild and severe <italic>SCN1A</italic> mutations (<xref ref-type="table" rid="pone.0211901.t003">Table 3</xref>).</p>
<p>Moreover, we tried to use the readily available tools for predicting secondary and tertiary protein structure to compare wild-type versus mutant Na<sub>V</sub>1.1 channels, but failed to reveal any misfolding (<xref ref-type="supplementary-material" rid="pone.0211901.s006">S5 Fig</xref>). These mathematical models predict protein structure by computing the position of atoms, which confers minimal energetic level and maximal stability to the protein structure, and aligning them against a template of homologous proteins with known crystallographic or MRI structure [<xref ref-type="bibr" rid="pone.0211901.ref029">29</xref>]. While these automated pipelines, such as SWISS-MODEL are user-friendly and can predict different functional domains, they are probably not sensitive enough to perceive perturbations caused by single point mutations. Thus, despite the high accessibility of bioinformatics servers to clinicians, they fail to predict the future clinical course.</p>
</sec>
<sec id="sec017">
<title>Functional studies of <italic>SCN1A</italic> mutations in expression systems can predict the degree of pathogenicity</title>
<p>In this study, three of the mutations tested (p.Gly177Ala, p.Ser259Arg and p.Glu1923Arg) indicated complete loss-of-function effect, while the p.Met1267Ile mutation demonstrated complex biophysical changes, likely to cause partial loss of function. The degree of <italic>in vitro</italic> loss of function correlates well with the severity of clinical phenotypes. Thus, we propose that lack of functional channels can predict an unfavorable outcome of <italic>de novo SCN1A</italic> missense mutations, while detectable currents, regardless of their biophysical properties, indicate milder phenotypes. Corroborating this, previous electrophysiological studies indexed in the <italic>SCN1A</italic> mutation database (<ext-link ext-link-type="uri" xlink:href="http://www.gzneurosci.com/scn1adatabase">http://www.gzneurosci.com/scn1adatabase</ext-link>) reported complete loss-of-function in 11 out of 19 Dravet missense mutations listed [<xref ref-type="bibr" rid="pone.0211901.ref030">30</xref>–<xref ref-type="bibr" rid="pone.0211901.ref036">36</xref>]. While detailed clinical information is missing for most of these mutations, thereby preventing the differentiation between classical and milder forms of Dravet [<xref ref-type="bibr" rid="pone.0211901.ref030">30</xref>, <xref ref-type="bibr" rid="pone.0211901.ref032">32</xref>, <xref ref-type="bibr" rid="pone.0211901.ref035">35</xref>], Volkers et al (2011) describe lower seizure burden in a functional mutation (p.Arg865Gly) versus a nonfunctional channel (p.Arg946Cys) [<xref ref-type="bibr" rid="pone.0211901.ref031">31</xref>]. Furthermore, febrile seizures and GEFS+ associated <italic>SCN1A</italic> missense mutations produce detectable current with an amplitude of at least 100 pA [<xref ref-type="bibr" rid="pone.0211901.ref023">23</xref>].</p>
<p>We thus propose the use of functional tests, using patch clamp analysis, as part of the diagnosis process. To date, patch clamp experiments are not readily available for clinicians. However, automated patch clamp set-ups are widely used in drug discovery companies, offering rapid and simple functional analysis of ion channel activity [<xref ref-type="bibr" rid="pone.0211901.ref037">37</xref>]. Therefore, functional analysis of <italic>de novo</italic> missense <italic>SCN1A</italic> mutations, using automated patch clamp systems, can be implemented as part of the personalized diagnostic procedure and may soon become as routine and straightforward as genetic analysis.</p>
<p>Our attempts to rescue the function of Na<sub>V</sub>1.1 mutants G177A, S259R and Q1923R by pharmacological chaperoning (Na<sub>V</sub>1.1-Compound 3a [<xref ref-type="bibr" rid="pone.0211901.ref017">17</xref>]) or by application of Hm1a were unsuccessful (<xref ref-type="supplementary-material" rid="pone.0211901.s002">S1</xref> and <xref ref-type="supplementary-material" rid="pone.0211901.s004">S3</xref> Figs). In contrast, the Hm1a toxin was able the increase the currents and reduce the inactivation of the M1267I mutation (<xref ref-type="supplementary-material" rid="pone.0211901.s002">S1 Fig</xref>). With further development of Na<sub>V</sub>1.1 openers for clinical use [<xref ref-type="bibr" rid="pone.0211901.ref038">38</xref>], functional analysis may provide information about the appropriate dosages. Mutations causing partial loss of function might foreseeably require lower dosages than mutations that confer complete loss of function.</p>
<p>To gain mechanistic insights about pathogenicity, neuronal systems such as cultured neurons or induced pluripotent stem cell (iPSC)-derived neurons may be needed. Moreover, genetic background greatly affects disease severity, especially in the case of inherited missense <italic>SCN1A</italic> mutations [<xref ref-type="bibr" rid="pone.0211901.ref010">10</xref>]. Indeed, three of the eight functional Dravet associated mutations (~40%) are familial mutations (p.Arg1648Cys [<xref ref-type="bibr" rid="pone.0211901.ref039">39</xref>], p.Arg1657Cys [<xref ref-type="bibr" rid="pone.0211901.ref033">33</xref>] p.Met1852Thr [<xref ref-type="bibr" rid="pone.0211901.ref036">36</xref>]), with mild and severe phenotypes within the same kindred. To study the role of modifier genes, mouse models and patient-derived neurons may be useful [<xref ref-type="bibr" rid="pone.0211901.ref040">40</xref>–<xref ref-type="bibr" rid="pone.0211901.ref047">47</xref>]. Foreseeably at this time, these preparations are neither automated nor likely to become accessible in the near future as part of routine clinical diagnosis.</p>
</sec>
<sec id="sec018">
<title>Clinical assessment of Dravet patients</title>
<p>Assessment of disease severity is challenging, as seizure burden and cognitive abilities of Dravet patients change with age. We compared the frequency of seizures and EEG background activity of patients at two and five years of age. Additionally, we administered the VABS test which, unlike other IQ or DQ tests, allows comparison of adaptive daily functions at different ages, irrespective of developmental level and cooperation. VABS has previously been used in two studies assessing cognition and behavior in children with Dravet [<xref ref-type="bibr" rid="pone.0211901.ref048">48</xref>, <xref ref-type="bibr" rid="pone.0211901.ref049">49</xref>]. This type of assessment suggested a distinctive profile for these children, with higher scores on the socialization domain, as compared to communication or living skills. While our cohort is small, our patients scored higher in the communication domain. Interestingly, two patients (p.Ser259Arg and p.Met1267Ile) scored within the normal range in the verbal receptive subdomain and discordantly low in daily living (personal, domestic and community) domain (<xref ref-type="table" rid="pone.0211901.t002">Table 2</xref>). These results reinforce the notion that Dravet patients may have a uniquely identifying functional profile, which distinguishes them from children with autism or intellectual disability. Our findings warrant further evaluation of larger patient cohorts using VABS.</p>
</sec>
</sec>
<sec id="sec019" sec-type="conclusions">
<title>Conclusion</title>
<p>Our data indicate that, while currently available bioinformatics tools are insufficient for predicting the severity of epilepsy and cognitive outcome, functional studies in mammalian expression systems may foretell the severity of <italic>de novo SCN1A</italic> missense mutations. Future technological development of automated patch-clamp set-ups, suitable for clinical use, may facilitate the inclusion of electrophysiological tests as part of a personalized diagnosis and treatment scheme for patients carrying <italic>de novo SCN1A</italic> mutations.</p>
</sec>
<sec id="sec020" sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material content-type="local-data" id="pone.0211901.s001">
<label>S1 Table</label>
<caption>
<title>Quantitative EEG evaluation of at two and five years of age.</title>
<p>Mean background frequencies and power band in left frontal F3 montage are depicted. No EEG`s are available for the patient with the p. Glu1923Arg mutation.</p>
<p>(PDF)</p>
</caption>
<media xlink:href="pone.0211901.s001.pdf">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pone.0211901.s002">
<label>S1 Fig</label>
<caption>
<title>Hm1a does not rescue the activity of Na<sub>V</sub>1.1 mutants G177A, S259R and Q1923R.</title>
<p>Currents from HEK-293 cells transiently expressing Na<sub>V</sub>1.1 channels in the absence (black) or presence (red) of 250 nM Hm1a. Currents were elicited by depolarizations to 0 mV from a holding potential of -120 mV. We calculated the effect of Hm1a as the difference in peak amplitude and inactivation (current at the end of the pulse / peak current) before and after Hm1a application. Hm1a increased the peak amplitude of Na<sub>V</sub>1.1<sup>WT</sup> by 16.8 ± 6.44%, and reduced the inactivation by 28.4 ± 3.57%. Comparable effects were measured for Na<sub>V</sub>1.1<sup>M1267I</sup> with 21.13 ± 8% increase of peak amplitude and 21.2 ± 7% reduction in inactivation.</p>
<p>(PDF)</p>
</caption>
<media xlink:href="pone.0211901.s002.pdf">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pone.0211901.s003">
<label>S2 Fig</label>
<caption>
<title>Na<sub>V</sub>1.1 expression in total membranes.</title>
<p>Representative immunoblots of Na<sub>V</sub>1.1 expression in total membranes. The rightmost lane represents untransfected HEK-293 cell (-). The lower panel is an Na<sup>+</sup>/K<sup>+</sup> ATPase loading control. The bar graph is a quantification of the normalized expression of three independent experiments. For each lane, Na<sub>V</sub>1.1 protein expression was first corrected to the relative expression of the Na<sup>+</sup>/K<sup>+</sup> ATPase loading control. Next, in order to combine different experiments, the data were further normalized to the corrected expression of Na<sub>V</sub>1.1<sup>WT</sup> in each experiment.</p>
<p>(PDF)</p>
</caption>
<media xlink:href="pone.0211901.s003.pdf">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pone.0211901.s004">
<label>S3 Fig</label>
<caption>
<title>Pharmacological chaperoning.</title>
<p>The effect of pharmacological chaperoning. The cells were incubated for 48-72h with 30 μM of the Na<sub>V</sub>1.1 modulator, N,N'-(1,3-phenylene)bis(2-methylbenzamide), also known as Na<sub>V</sub>1.1-Compound 3a. The drug was not included in the external recording solution to prevent a reduction in peak amplitude. (A) Representative set of sodium current traces from HEK-293 cells expressing Na<sub>V</sub>1.1<sup>WT</sup>, Na<sub>V</sub>1.1<sup>G177A</sup>, Na<sub>V</sub>1.1<sup>S259R</sup> or Na<sub>V</sub>1.1<sup>Q1923R</sup>. (B) Mean current-voltage (I-V) relationships of sodium current densities. Na<sub>V</sub>1.1<sup>WT</sup> n = 12; Na<sub>V</sub>1.1<sup>G177A</sup> n = 10; Na<sub>V</sub>1.1<sup>S259R</sup> n = 7; Na<sub>V</sub>1.1<sup>Q1923R</sup> n = 7. (C) Average current densities at -10 mV, with or without (Cnt) incubation with Na<sub>V</sub>1.1-Compound 3a.</p>
<p>(PDF)</p>
</caption>
<media xlink:href="pone.0211901.s004.pdf">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pone.0211901.s005">
<label>S4 Fig</label>
<caption>
<title>Na<sub>V</sub>1.1<sup>WT</sup> and Na<sub>V</sub>1.1<sup>M1267I</sup>.</title>
<p>(A) Mean current–voltage (I–V) relationships of peak currents for Na<sub>V</sub>1.1<sup>WT</sup> and Na<sub>V</sub>1.1<sup>M1267I</sup>, not normalized to cell capacitance. (B) Persistent currents (% of peak currents) measured at the end of 20 ms depolarization to 0 mV.</p>
<p>(PDF)</p>
</caption>
<media xlink:href="pone.0211901.s005.pdf">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pone.0211901.s006">
<label>S5 Fig</label>
<caption>
<title>Homology modeling.</title>
<p>Homology modeling of WT (A,C,E,G) and mutant Na<sub>V</sub>1.1 (B,D,F,H).</p>
<p>(PDF)</p>
</caption>
<media xlink:href="pone.0211901.s006.pdf">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>We thank Ms. Karen Anderson for scientific and English editing.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0211901.ref001">
<label>1</label>
<mixed-citation publication-type="journal"><name><surname>Dravet</surname><given-names>C</given-names></name>. <article-title>The core Dravet syndrome phenotype</article-title>. <source/>Epilepsia. <year>2011</year>;<volume>52</volume>
<fpage>3</fpage>–<lpage>9</lpage>.</mixed-citation>
</ref>
<ref id="pone.0211901.ref002">
<label>2</label>
<mixed-citation publication-type="journal"><name><surname>Lagae</surname><given-names>L</given-names></name>, <name><surname>Brambilla</surname><given-names>I</given-names></name>, <name><surname>Mingorance</surname><given-names>A</given-names></name>, <name><surname>Gibson</surname><given-names>E</given-names></name>, <name><surname>Battersby</surname><given-names>A</given-names></name>. <article-title>Quality of life and comorbidities associated with Dravet syndrome severity: a multinational cohort survey</article-title>. <source/>Developmental medicine and child neurology. <year>2018</year>;<volume>60</volume>(<issue>1</issue>):<fpage>63</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1111/dmcn.13591</pub-id>
<pub-id pub-id-type="pmid">28984349</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref003">
<label>3</label>
<mixed-citation publication-type="journal"><name><surname>Claes</surname><given-names>L</given-names></name>, <name><surname>Del-Favero</surname><given-names>J</given-names></name>, <name><surname>Ceulemans</surname><given-names>B</given-names></name>, <name><surname>Lagae</surname><given-names>L</given-names></name>, <name><surname>Van Broeckhoven</surname><given-names>C</given-names></name>, <name><surname>De Jonghe</surname><given-names>P</given-names></name>. <article-title><italic>De novo</italic> mutations in the sodium-channel gene <italic>SCN1A</italic> cause severe myoclonic epilepsy of infancy</article-title>. <source/>American journal of human genetics. <year>2001</year>;<volume>68</volume>(<issue>6</issue>):<fpage>1327</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1086/320609</pub-id>
<pub-id pub-id-type="pmid">11359211</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref004">
<label>4</label>
<mixed-citation publication-type="journal"><name><surname>Cooper</surname><given-names>MS</given-names></name>, <name><surname>McIntosh</surname><given-names>A</given-names></name>, <name><surname>Crompton</surname><given-names>DE</given-names></name>, <name><surname>McMahon</surname><given-names>JM</given-names></name>, <name><surname>Schneider</surname><given-names>A</given-names></name>, <name><surname>Farrell</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Mortality in Dravet syndrome</article-title>. <source/>Epilepsy Research. <year>2016</year>;<volume>128</volume>:<fpage>43</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.eplepsyres.2016.10.006</pub-id>
<pub-id pub-id-type="pmid">27810515</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref005">
<label>5</label>
<mixed-citation publication-type="journal"><name><surname>Wirrell</surname><given-names>EC</given-names></name>, <name><surname>Laux</surname><given-names>L</given-names></name>, <name><surname>Donner</surname><given-names>E</given-names></name>, <name><surname>Jette</surname><given-names>N</given-names></name>, <name><surname>Knupp</surname><given-names>K</given-names></name>, <name><surname>Meskis</surname><given-names>MA</given-names></name>, <etal>et al</etal>
<article-title>Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American consensus panel</article-title>. <source/>Pediatric neurology. <year>2017</year>;<volume>68</volume>:<fpage>18</fpage>–<lpage>34 e3</lpage>. <pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2017.01.025</pub-id>
<pub-id pub-id-type="pmid">28284397</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref006">
<label>6</label>
<mixed-citation publication-type="journal"><name><surname>Zuberi</surname><given-names>SM</given-names></name>, <name><surname>Brunklaus</surname><given-names>A</given-names></name>, <name><surname>Birch</surname><given-names>R</given-names></name>, <name><surname>Reavey</surname><given-names>E</given-names></name>, <name><surname>Duncan</surname><given-names>J</given-names></name>, <name><surname>Forbes</surname><given-names>GH</given-names></name>. <article-title>Genotype-phenotype associations in <italic>SCN1A</italic>-related epilepsies</article-title>. <source/>Neurology. <year>2011</year>;<volume>76</volume>(<issue>7</issue>):<fpage>594</fpage>–<lpage>600</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0b013e31820c309b</pub-id>
<pub-id pub-id-type="pmid">21248271</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref007">
<label>7</label>
<mixed-citation publication-type="journal"><name><surname>Dravet</surname><given-names>C</given-names></name>, <name><surname>Bureau</surname><given-names>M</given-names></name>, <name><surname>Oguni</surname><given-names>H</given-names></name>, <name><surname>Fukuyama</surname><given-names>Y</given-names></name>, <name><surname>Cokar</surname><given-names>O</given-names></name>. <article-title>Severe myoclonic epilepsy in infancy: Dravet syndrome</article-title>. <source/>Adv Neurol. <year>2005</year>;<volume>95</volume>:<fpage>71</fpage>–<lpage>102</lpage>. <pub-id pub-id-type="pmid">15508915</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref008">
<label>8</label>
<mixed-citation publication-type="journal"><name><surname>Scheffer</surname><given-names>IE</given-names></name>. <article-title>Diagnosis and long-term course of Dravet syndrome</article-title>. <source/>European journal of paediatric neurology: EJPN: official journal of the European Paediatric Neurology Society. <year>2012</year>;<volume>16</volume>
<issue>Suppl 1</issue>:<fpage>S5</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">22704920</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref009">
<label>9</label>
<mixed-citation publication-type="journal"><name><surname>Meng</surname><given-names>H</given-names></name>, <name><surname>Xu</surname><given-names>HQ</given-names></name>, <name><surname>Yu</surname><given-names>L</given-names></name>, <name><surname>Lin</surname><given-names>GW</given-names></name>, <name><surname>He</surname><given-names>N</given-names></name>, <name><surname>Su</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>The <italic>SCN1A</italic> mutation database: updating information and analysis of the relationships among genotype, functional alteration, and phenotype</article-title>. <source/>Human mutation. <year>2015</year>;<volume>36</volume>(<issue>6</issue>):<fpage>573</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1002/humu.22782</pub-id>
<pub-id pub-id-type="pmid">25754450</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref010">
<label>10</label>
<mixed-citation publication-type="journal"><name><surname>Guerrini</surname><given-names>R</given-names></name>, <name><surname>Cellini</surname><given-names>E</given-names></name>, <name><surname>Mei</surname><given-names>D</given-names></name>, <name><surname>Metitieri</surname><given-names>T</given-names></name>, <name><surname>Petrelli</surname><given-names>C</given-names></name>, <name><surname>Pucatti</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Variable epilepsy phenotypes associated with a familial intragenic deletion of the <italic>SCN1A</italic> gene</article-title>. <source/>Epilepsia. <year>2010</year>;<volume>51</volume>(<issue>12</issue>):<fpage>2474</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/j.1528-1167.2010.02790.x</pub-id>
<pub-id pub-id-type="pmid">21204810</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref011">
<label>11</label>
<mixed-citation publication-type="journal"><name><surname>Hawkins</surname><given-names>NA</given-names></name>, <name><surname>Zachwieja</surname><given-names>NJ</given-names></name>, <name><surname>Miller</surname><given-names>AR</given-names></name>, <name><surname>Anderson</surname><given-names>LL</given-names></name>, <name><surname>Kearney</surname><given-names>JA</given-names></name>. <article-title>Fine mapping of a Dravet syndrome modifier locus on mouse chromosome 5 and candidate gene analysis by RNA-Seq</article-title>. <source/>PLoS genetics. <year>2016</year>;<volume>12</volume>(<issue>10</issue>):<fpage>e1006398</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1006398</pub-id>
<pub-id pub-id-type="pmid">27768696</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref012">
<label>12</label>
<mixed-citation publication-type="journal"><name><surname>Miller</surname><given-names>AR</given-names></name>, <name><surname>Hawkins</surname><given-names>NA</given-names></name>, <name><surname>McCollom</surname><given-names>CE</given-names></name>, <name><surname>Kearney</surname><given-names>JA</given-names></name>. <article-title>Mapping genetic modifiers of survival in a mouse model of Dravet syndrome</article-title>. <source/>Genes, Brain and Behavior. <year>2013</year>;<volume>13</volume>(<issue>2</issue>):<fpage>163</fpage>–<lpage>72</lpage>.</mixed-citation>
</ref>
<ref id="pone.0211901.ref013">
<label>13</label>
<mixed-citation publication-type="journal"><name><surname>Holmes</surname><given-names>GL</given-names></name>, <name><surname>Bender</surname><given-names>AC</given-names></name>, <name><surname>Wu</surname><given-names>EX</given-names></name>, <name><surname>Scott</surname><given-names>RC</given-names></name>, <name><surname>Lenck-Santini</surname><given-names>PP</given-names></name>, <name><surname>Morse</surname><given-names>RP</given-names></name>. <article-title>Maturation of EEG oscillations in children with sodium channel mutations</article-title>. <source/>Brain &amp; development. <year>2012</year>;<volume>34</volume>(<issue>6</issue>):<fpage>469</fpage>–<lpage>77</lpage>.<pub-id pub-id-type="pmid">21940124</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref014">
<label>14</label>
<mixed-citation publication-type="book"><name><surname>Sparrow</surname><given-names>SS</given-names></name>, <name><surname>Cicchetti</surname><given-names>DV</given-names></name>, <name><surname>Balla</surname><given-names>DA</given-names></name>. <source/>Vineland-II adaptive behavior scales: survey forms manual. <edition>Second Edition</edition> ed. <publisher-loc>Minneapolis, USA</publisher-loc>: <publisher-name>AGS Publishing</publisher-name>; <year>2005</year></mixed-citation>
</ref>
<ref id="pone.0211901.ref015">
<label>15</label>
<mixed-citation publication-type="journal"><name><surname>Baek</surname><given-names>JH</given-names></name>, <name><surname>Rubinstein</surname><given-names>M</given-names></name>, <name><surname>Scheuer</surname><given-names>T</given-names></name>, <name><surname>Trimmer</surname><given-names>JS</given-names></name>. <article-title>Reciprocal changes in phosphorylation and methylation of mammalian brain sodium channels in response to seizures</article-title>. <source/>The Journal of biological chemistry. <year>2014</year>; <volume>289</volume>(<issue>22</issue>): <fpage>15363</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M114.562785</pub-id>
<pub-id pub-id-type="pmid">24737319</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref016">
<label>16</label>
<mixed-citation publication-type="journal"><name><surname>Osteen</surname><given-names>JD</given-names></name>, <name><surname>Herzig</surname><given-names>V</given-names></name>, <name><surname>Gilchrist</surname><given-names>J</given-names></name>, <name><surname>Emrick</surname><given-names>JJ</given-names></name>, <name><surname>Zhang</surname><given-names>C</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>, <etal>et al</etal>
<article-title>Selective spider toxins reveal a role for the Na<sub>V</sub>1.1 channel in mechanical pain</article-title>. <source/>Nature. <year>2016</year>;<volume>534</volume>(<issue>7608</issue>):<fpage>494</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nature17976</pub-id>
<pub-id pub-id-type="pmid">27281198</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref017">
<label>17</label>
<mixed-citation publication-type="journal"><name><surname>Crestey</surname><given-names>F</given-names></name>, <name><surname>Frederiksen</surname><given-names>K</given-names></name>, <name><surname>Jensen</surname><given-names>HS</given-names></name>, <name><surname>Dekermendjian</surname><given-names>K</given-names></name>, <name><surname>Larsen</surname><given-names>PH</given-names></name>, <name><surname>Bastlund</surname><given-names>JF</given-names></name>, <etal>et al</etal>
<article-title>Identification and electrophysiological evaluation of 2-methylbenzamide derivatives as Na<sub>V</sub>1.1 modulators</article-title>. <source/>ACS chemical neuroscience. <year>2015</year>;<volume>6</volume>(<issue>8</issue>):<fpage>1302</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1021/acschemneuro.5b00147</pub-id>
<pub-id pub-id-type="pmid">26114759</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref018">
<label>18</label>
<mixed-citation publication-type="journal"><name><surname>Kumar</surname><given-names>P</given-names></name>, <name><surname>Henikoff</surname><given-names>S</given-names></name>, <name><surname>Ng</surname><given-names>PC</given-names></name>. <article-title>Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm</article-title>. <source/>Nature protocols. <year>2009</year>;<volume>4</volume>(<issue>7</issue>):<fpage>1073</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2009.86</pub-id>
<pub-id pub-id-type="pmid">19561590</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref019">
<label>19</label>
<mixed-citation publication-type="journal"><name><surname>Reva</surname><given-names>B</given-names></name>, <name><surname>Antipin</surname><given-names>Y</given-names></name>, <name><surname>Sander</surname><given-names>C</given-names></name>. <article-title>Predicting the functional impact of protein mutations: application to cancer genomics</article-title>. <source/>Nucleic acids research. <year>2011</year>;<volume>39</volume>(<issue>17</issue>):<fpage>e118</fpage>
<pub-id pub-id-type="doi">10.1093/nar/gkr407</pub-id>
<pub-id pub-id-type="pmid">21727090</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref020">
<label>20</label>
<mixed-citation publication-type="journal"><name><surname>Adzhubei</surname><given-names>IA</given-names></name>, <name><surname>Schmidt</surname><given-names>S</given-names></name>, <name><surname>Peshkin</surname><given-names>L</given-names></name>, <name><surname>Ramensky</surname><given-names>VE</given-names></name>, <name><surname>Gerasimova</surname><given-names>A</given-names></name>, <name><surname>Bork</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>A method and server for predicting damaging missense mutations</article-title>. <source/>Nature methods. <year>2010</year>;<volume>7</volume>(<issue>4</issue>):<fpage>248</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth0410-248</pub-id>
<pub-id pub-id-type="pmid">20354512</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref021">
<label>21</label>
<mixed-citation publication-type="journal"><name><surname>Gonzalez-Perez</surname><given-names>A</given-names></name>, <name><surname>Lopez-Bigas</surname><given-names>N</given-names></name>. <article-title>Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel</article-title>. <source/>American journal of human genetics. <year>2011</year>;<volume>88</volume>(<issue>4</issue>):<fpage>440</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2011.03.004</pub-id>
<pub-id pub-id-type="pmid">21457909</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref022">
<label>22</label>
<mixed-citation publication-type="journal"><name><surname>Choi</surname><given-names>Y</given-names></name>, <name><surname>Chan</surname><given-names>AP</given-names></name>. <article-title>PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels</article-title>. <source/>Bioinformatics (Oxford, England). <year>2015</year>;<volume>31</volume>(<issue>16</issue>):<fpage>2745</fpage>–<lpage>7</lpage>.</mixed-citation>
</ref>
<ref id="pone.0211901.ref023">
<label>23</label>
<mixed-citation publication-type="journal"><name><surname>Bechi</surname><given-names>G</given-names></name>, <name><surname>Rusconi</surname><given-names>R</given-names></name>, <name><surname>Cestele</surname><given-names>S</given-names></name>, <name><surname>Striano</surname><given-names>P</given-names></name>, <name><surname>Franceschetti</surname><given-names>S</given-names></name>, <name><surname>Mantegazza</surname><given-names>M</given-names></name>. <article-title>Rescuable folding defective Na<sub>V</sub>1.1 (<italic>SCN1A</italic>) mutants in epilepsy: properties, occurrence, and novel rescuing strategy with peptides targeted to the endoplasmic reticulum</article-title>. <source/>Neurobiology of disease. <year>2015</year>;<volume>75</volume>:<fpage>100</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2014.12.028</pub-id>
<pub-id pub-id-type="pmid">25576396</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref024">
<label>24</label>
<mixed-citation publication-type="journal"><name><surname>Mantegazza</surname><given-names>M</given-names></name>, <name><surname>Gambardella</surname><given-names>A</given-names></name>, <name><surname>Rusconi</surname><given-names>R</given-names></name>, <name><surname>Schiavon</surname><given-names>E</given-names></name>, <name><surname>Annesi</surname><given-names>F</given-names></name>, <name><surname>Cassulini</surname><given-names>RR</given-names></name>, <etal>et al</etal>
<article-title>Identification of an Na<sub>V</sub>1.1 sodium channel (<italic>SCN1A</italic>) loss-of-function mutation associated with familial simple febrile seizures</article-title>. <source/>Proceedings of the National Academy of Sciences of the United States of America. <year>2005</year>;<volume>102</volume>(<issue>50</issue>):<fpage>18177</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0506818102</pub-id>
<pub-id pub-id-type="pmid">16326807</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref025">
<label>25</label>
<mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>YW</given-names></name>, <name><surname>Sullivan</surname><given-names>J</given-names></name>, <name><surname>McDaniel</surname><given-names>SS</given-names></name>, <name><surname>Meisler</surname><given-names>MH</given-names></name>, <name><surname>Walsh</surname><given-names>EM</given-names></name>, <name><surname>Li</surname><given-names>SX</given-names></name>, <etal>et al</etal>
<article-title>Incidence of Dravet syndrome in a US population</article-title>. <source/>Pediatrics. <year>2015</year>;<volume>136</volume>(<issue>5</issue>):<fpage>e1310</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2015-1807</pub-id>
<pub-id pub-id-type="pmid">26438699</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref026">
<label>26</label>
<mixed-citation publication-type="journal"><name><surname>Catterall</surname><given-names>WA</given-names></name>, <name><surname>Kalume</surname><given-names>F</given-names></name>, <name><surname>Oakley</surname><given-names>JC</given-names></name>. <article-title>Na<sub>V</sub>1.1 channels and epilepsy</article-title>. <source/>J Physiol. <year>2010</year>;<volume>588</volume>(<issue>11</issue>):<fpage>1849</fpage>–<lpage>59</lpage>.<pub-id pub-id-type="pmid">20194124</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref027">
<label>27</label>
<mixed-citation publication-type="journal"><name><surname>Ziobro</surname><given-names>J</given-names></name>, <name><surname>Eschbach</surname><given-names>K</given-names></name>, <name><surname>Sullivan</surname><given-names>JE</given-names></name>, <name><surname>Knupp</surname><given-names>KG</given-names></name>. <article-title>Current treatment strategies and future treatment options for Dravet syndrome</article-title>. <source/>Current treatment options in neurology. <year>2018</year>;<volume>20</volume>(<issue>12</issue>):<fpage>52</fpage>
<pub-id pub-id-type="doi">10.1007/s11940-018-0537-y</pub-id>
<pub-id pub-id-type="pmid">30315507</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref028">
<label>28</label>
<mixed-citation publication-type="journal"><name><surname>Cetica</surname><given-names>V</given-names></name>, <name><surname>Chiari</surname><given-names>S</given-names></name>, <name><surname>Mei</surname><given-names>D</given-names></name>, <name><surname>Parrini</surname><given-names>E</given-names></name>, <name><surname>Grisotto</surname><given-names>L</given-names></name>, <name><surname>Marini</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Clinical and genetic factors predicting Dravet syndrome in infants with <italic>SCN1A</italic> mutations</article-title>. <source/>Neurology. <year>2017</year>;<volume>88</volume>(<issue>11</issue>):<fpage>1037</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000003716</pub-id>
<pub-id pub-id-type="pmid">28202706</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref029">
<label>29</label>
<mixed-citation publication-type="book"><name><surname>Mullins</surname><given-names>JGL</given-names></name>. <chapter-title>Chapter five—structural modelling pipelines in Next Generation Sequencing projects</chapter-title> In: <name><surname>Rees</surname><given-names>MI</given-names></name>, editor. <source/>Advances in Protein Chemistry and Structural Biology. <volume>89</volume>: <publisher-name>Academic Press</publisher-name>; <year>2012</year> p. <fpage>117</fpage>–<lpage>67</lpage>.<pub-id pub-id-type="pmid">23046884</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref030">
<label>30</label>
<mixed-citation publication-type="journal"><name><surname>Ohmori</surname><given-names>I</given-names></name>, <name><surname>Kahlig</surname><given-names>KM</given-names></name>, <name><surname>Rhodes</surname><given-names>TH</given-names></name>, <name><surname>Wang</surname><given-names>DW</given-names></name>, <name><surname>George</surname><given-names>AL</given-names><suffix>Jr</suffix></name>. <article-title>Nonfunctional <italic>SCN1A</italic> is common in severe myoclonic epilepsy of infancy</article-title>. <source/>Epilepsia. <year>2006</year>;<volume>47</volume>(<issue>10</issue>):<fpage>1636</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1111/j.1528-1167.2006.00643.x</pub-id>
<pub-id pub-id-type="pmid">17054685</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref031">
<label>31</label>
<mixed-citation publication-type="journal"><name><surname>Volkers</surname><given-names>L</given-names></name>, <name><surname>Kahlig</surname><given-names>KM</given-names></name>, <name><surname>Verbeek</surname><given-names>NE</given-names></name>, <name><surname>Das</surname><given-names>JH</given-names></name>, <name><surname>van Kempen</surname><given-names>MJ</given-names></name>, <name><surname>Stroink</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Nav 1.1 dysfunction in genetic epilepsy with febrile seizures-plus or Dravet syndrome</article-title>. <source/>The European journal of neuroscience. <year>2011</year>;<volume>34</volume>(<issue>8</issue>):<fpage>1268</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1111/j.1460-9568.2011.07826.x</pub-id>
<pub-id pub-id-type="pmid">21864321</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref032">
<label>32</label>
<mixed-citation publication-type="journal"><name><surname>Sugawara</surname><given-names>T</given-names></name>, <name><surname>Tsurubuchi</surname><given-names>Y</given-names></name>, <name><surname>Fujiwara</surname><given-names>T</given-names></name>, <name><surname>Mazaki-Miyazaki</surname><given-names>E</given-names></name>, <name><surname>Nagata</surname><given-names>K</given-names></name>, <name><surname>Montal</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Nav1.1 channels with mutations of severe myoclonic epilepsy in infancy display attenuated currents</article-title>. <source/>Epilepsy Res. <year>2003</year>;<volume>54</volume>(<issue>2–3</issue>):<fpage>201</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="pmid">12837571</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref033">
<label>33</label>
<mixed-citation publication-type="journal"><name><surname>Lossin</surname><given-names>C</given-names></name>, <name><surname>Rhodes</surname><given-names>TH</given-names></name>, <name><surname>Desai</surname><given-names>RR</given-names></name>, <name><surname>Vanoye</surname><given-names>CG</given-names></name>, <name><surname>Wang</surname><given-names>D</given-names></name>, <name><surname>Carniciu</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Epilepsy-associated dysfunction in the voltage-gated neuronal sodium channel <italic>SCN1A</italic></article-title>. <source/>The Journal of neuroscience: the official journal of the Society for Neuroscience. <year>2003</year>;<volume>23</volume>(<issue>36</issue>):<fpage>11289</fpage>–<lpage>95</lpage>.<pub-id pub-id-type="pmid">14672992</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref034">
<label>34</label>
<mixed-citation publication-type="journal"><name><surname>Rhodes</surname><given-names>TH</given-names></name>, <name><surname>Vanoye</surname><given-names>CG</given-names></name>, <name><surname>Ohmori</surname><given-names>I</given-names></name>, <name><surname>Ogiwara</surname><given-names>I</given-names></name>, <name><surname>Yamakawa</surname><given-names>K</given-names></name>, <name><surname>George</surname><given-names>AL</given-names><suffix>Jr</suffix></name>. <article-title>Sodium channel dysfunction in intractable childhood epilepsy with generalized tonic-clonic seizures</article-title>. <source/>J Physiol. <year>2005</year>;<volume>569</volume>(<issue>Pt 2</issue>):<fpage>433</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.2005.094326</pub-id>
<pub-id pub-id-type="pmid">16210358</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref035">
<label>35</label>
<mixed-citation publication-type="journal"><name><surname>Rhodes</surname><given-names>TH</given-names></name>, <name><surname>Lossin</surname><given-names>C</given-names></name>, <name><surname>Vanoye</surname><given-names>CG</given-names></name>, <name><surname>Wang</surname><given-names>DW</given-names></name>, <name><surname>George</surname><given-names>AL</given-names><suffix>Jr</suffix></name>. <article-title>Noninactivating voltage-gated sodium channels in severe myoclonic epilepsy of infancy</article-title>. <source/>Proceedings of the National Academy of Sciences of the United States of America. <year>2004</year>;<volume>101</volume>(<issue>30</issue>):<fpage>11147</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0402482101</pub-id>
<pub-id pub-id-type="pmid">15263074</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref036">
<label>36</label>
<mixed-citation publication-type="journal"><name><surname>Rusconi</surname><given-names>R</given-names></name>, <name><surname>Scalmani</surname><given-names>P</given-names></name>, <name><surname>Cassulini</surname><given-names>RR</given-names></name>, <name><surname>Giunti</surname><given-names>G</given-names></name>, <name><surname>Gambardella</surname><given-names>A</given-names></name>, <name><surname>Franceschetti</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Modulatory proteins can rescue a trafficking defective epileptogenic Na<sub>V</sub>1.1 Na<sup>+</sup> channel mutant</article-title>. <source/>The Journal of neuroscience: the official journal of the Society for Neuroscience. <year>2007</year>;<volume>27</volume>(<issue>41</issue>):<fpage>11037</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="pmid">17928445</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref037">
<label>37</label>
<mixed-citation publication-type="journal"><name><surname>Obergrussberger</surname><given-names>A</given-names></name>, <name><surname>Goetze</surname><given-names>TA</given-names></name>, <name><surname>Brinkwirth</surname><given-names>N</given-names></name>, <name><surname>Becker</surname><given-names>N</given-names></name>, <name><surname>Friis</surname><given-names>S</given-names></name>, <name><surname>Rapedius</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>An update on the advancing high-throughput screening techniques for patch clamp-based ion channel screens: implications for drug discovery</article-title>. <source/>Expert opinion on drug discovery. <year>2018</year>;<volume>13</volume>(<issue>3</issue>):<fpage>269</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1080/17460441.2018.1428555</pub-id>
<pub-id pub-id-type="pmid">29343120</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref038">
<label>38</label>
<mixed-citation publication-type="journal"><name><surname>Richards</surname><given-names>KL</given-names></name>, <name><surname>Milligan</surname><given-names>CJ</given-names></name>, <name><surname>Richardson</surname><given-names>RJ</given-names></name>, <name><surname>Jancovski</surname><given-names>N</given-names></name>, <name><surname>Grunnet</surname><given-names>M</given-names></name>, <name><surname>Jacobson</surname><given-names>LH</given-names></name>, <etal>et al</etal>
<article-title>Selective Na<sub>V</sub>1.1 activation rescues Dravet syndrome mice from seizures and premature death</article-title>. <source/>Proceedings of the National Academy of Sciences of the United States of America. <year>2018</year>;<volume>115</volume>(<issue>34</issue>):<fpage>E8077</fpage>–<lpage>E85</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1804764115</pub-id>
<pub-id pub-id-type="pmid">30076230</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref039">
<label>39</label>
<mixed-citation publication-type="journal"><name><surname>Ohmori</surname><given-names>I</given-names></name>, <name><surname>Ouchida</surname><given-names>M</given-names></name>, <name><surname>Ohtsuka</surname><given-names>Y</given-names></name>, <name><surname>Oka</surname><given-names>E</given-names></name>, <name><surname>Shimizu</surname><given-names>K</given-names></name>. <article-title>Significant correlation of the <italic>SCN1A</italic> mutations and severe myoclonic epilepsy in infancy</article-title>. <source/>Biochemical and biophysical research communications. <year>2002</year>;<volume>295</volume>(<issue>1</issue>):<fpage>17</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="pmid">12083760</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref040">
<label>40</label>
<mixed-citation publication-type="journal"><name><surname>Mistry</surname><given-names>AM</given-names></name>, <name><surname>Thompson</surname><given-names>CH</given-names></name>, <name><surname>Miller</surname><given-names>AR</given-names></name>, <name><surname>Vanoye</surname><given-names>CG</given-names></name>, <name><surname>George</surname><given-names>AL</given-names><suffix>Jr.</suffix></name>, <name><surname>Kearney</surname><given-names>JA</given-names></name>. <article-title>Strain- and age-dependent hippocampal neuron sodium currents correlate with epilepsy severity in Dravet syndrome mice</article-title>. <source/>Neurobiology of disease. <year>2014</year>;<volume>65</volume>:<fpage>1</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2014.01.006</pub-id>
<pub-id pub-id-type="pmid">24434335</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref041">
<label>41</label>
<mixed-citation publication-type="journal"><name><surname>Ogiwara</surname><given-names>I</given-names></name>, <name><surname>Miyamoto</surname><given-names>H</given-names></name>, <name><surname>Morita</surname><given-names>N</given-names></name>, <name><surname>Atapour</surname><given-names>N</given-names></name>, <name><surname>Mazaki</surname><given-names>E</given-names></name>, <name><surname>Inoue</surname><given-names>I</given-names></name>, <etal>et al</etal>
<article-title>Na<sub>V</sub>1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation</article-title>. <source/>The Journal of neuroscience: the official journal of the Society for Neuroscience. <year>2007</year>;<volume>27</volume>(<issue>22</issue>):<fpage>5903</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="pmid">17537961</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref042">
<label>42</label>
<mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>FH</given-names></name>, <name><surname>Mantegazza</surname><given-names>M</given-names></name>, <name><surname>Westenbroek</surname><given-names>RE</given-names></name>, <name><surname>Robbins</surname><given-names>CA</given-names></name>, <name><surname>Kalume</surname><given-names>F</given-names></name>, <name><surname>Burton</surname><given-names>KA</given-names></name>, <etal>et al</etal>
<article-title>Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy</article-title>. <source/>Nat Neurosci. <year>2006</year>;<volume>9</volume>(<issue>9</issue>):<fpage>1142</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nn1754</pub-id>
<pub-id pub-id-type="pmid">16921370</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref043">
<label>43</label>
<mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>HW</given-names></name>, <name><surname>Quan</surname><given-names>Z</given-names></name>, <name><surname>Kim</surname><given-names>YB</given-names></name>, <name><surname>Cheong</surname><given-names>E</given-names></name>, <name><surname>Kim</surname><given-names>HD</given-names></name>, <name><surname>Cho</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Differential effects on sodium current impairments by distinct <italic>SCN1A</italic> mutations in GABAergic neurons derived from Dravet syndrome patients</article-title>. <source/>Brain &amp; development. <year>2017</year>.</mixed-citation>
</ref>
<ref id="pone.0211901.ref044">
<label>44</label>
<mixed-citation publication-type="journal"><name><surname>Sun</surname><given-names>Y</given-names></name>, <name><surname>Pasca</surname><given-names>SP</given-names></name>, <name><surname>Portmann</surname><given-names>T</given-names></name>, <name><surname>Goold</surname><given-names>C</given-names></name>, <name><surname>Worringer</surname><given-names>KA</given-names></name>, <name><surname>Guan</surname><given-names>W</given-names></name>, <etal>et al</etal>
<article-title>A deleterious Na<sub>V</sub>1.1 mutation selectively impairs telencephalic inhibitory neurons derived from Dravet syndrome patients</article-title>. <source/>eLife. <year>2016</year>;<volume>5</volume>:<fpage>e13073</fpage>
<pub-id pub-id-type="doi">10.7554/eLife.13073</pub-id>
<pub-id pub-id-type="pmid">27458797</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref045">
<label>45</label>
<mixed-citation publication-type="journal"><name><surname>Jiao</surname><given-names>J</given-names></name>, <name><surname>Yang</surname><given-names>Y</given-names></name>, <name><surname>Shi</surname><given-names>Y</given-names></name>, <name><surname>Chen</surname><given-names>J</given-names></name>, <name><surname>Gao</surname><given-names>R</given-names></name>, <name><surname>Fan</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Modeling Dravet syndrome using induced pluripotent stem cells (iPSCs) and directly converted neurons</article-title>. <source/>Human molecular genetics. <year>2013</year>;<volume>22</volume>(<issue>21</issue>):<fpage>4241</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddt275</pub-id>
<pub-id pub-id-type="pmid">23773995</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref046">
<label>46</label>
<mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Lopez-Santiago</surname><given-names>LF</given-names></name>, <name><surname>Yuan</surname><given-names>Y</given-names></name>, <name><surname>Jones</surname><given-names>JM</given-names></name>, <name><surname>Zhang</surname><given-names>H</given-names></name>, <name><surname>O’Malley</surname><given-names>HA</given-names></name>, <etal>et al</etal>
<article-title>Dravet syndrome patient-derived neurons suggest a novel epilepsy mechanism</article-title>. <source/>Annals of neurology. <year>2013</year>;<volume>74</volume>(<issue>1</issue>):<fpage>128</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1002/ana.23897</pub-id>
<pub-id pub-id-type="pmid">23821540</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref047">
<label>47</label>
<mixed-citation publication-type="journal"><name><surname>Rubinstein</surname><given-names>M</given-names></name>, <name><surname>Westenbroek</surname><given-names>RE</given-names></name>, <name><surname>Yu</surname><given-names>FH</given-names></name>, <name><surname>Jones</surname><given-names>CJ</given-names></name>, <name><surname>Scheuer</surname><given-names>T</given-names></name>, <name><surname>Catterall</surname><given-names>WA</given-names></name>. <article-title>Genetic background modulates impaired excitability of inhibitory neurons in a mouse model of Dravet syndrome</article-title>. <source/>Neurobiology of disease. <year>2015</year>;<volume>73</volume>:<fpage>106</fpage>–<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2014.09.017</pub-id>
<pub-id pub-id-type="pmid">25281316</pub-id></mixed-citation>
</ref>
<ref id="pone.0211901.ref048">
<label>48</label>
<mixed-citation publication-type="journal"><name><surname>Do</surname><given-names>TT</given-names></name>, <name><surname>Vu</surname><given-names>DM</given-names></name>, <name><surname>Huynh</surname><given-names>TT</given-names></name>, <name><surname>Le</surname><given-names>TK</given-names></name>, <name><surname>Sohn</surname><given-names>EH</given-names></name>, <name><surname>Le</surname><given-names>TM</given-names></name>, <etal>et al</etal>
<article-title><italic>SCN1A</italic> gene mutation and adaptive functioning in 18 Vietnamese children with Dravet syndrome</article-title>. <source/>Journal of clinical neurology (Seoul, Korea). <year>2017</year>;<volume>13</volume>(<issue>1</issue>):<fpage>62</fpage>–<lpage>70</lpage>.</mixed-citation>
</ref>
<ref id="pone.0211901.ref049">
<label>49</label>
<mixed-citation publication-type="journal"><name><surname>Villeneuve</surname><given-names>N</given-names></name>, <name><surname>Laguitton</surname><given-names>V</given-names></name>, <name><surname>Viellard</surname><given-names>M</given-names></name>, <name><surname>Lepine</surname><given-names>A</given-names></name>, <name><surname>Chabrol</surname><given-names>B</given-names></name>, <name><surname>Dravet</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Cognitive and adaptive evaluation of 21 consecutive patients with Dravet syndrome</article-title>. <source/>Epilepsy &amp; behavior: E&amp;B. <year>2014</year>;<volume>31</volume>:<fpage>143</fpage>–<lpage>8</lpage>.</mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>